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Introduction 
SARCOMA 
Sarcomas are relatively rare mesenchymal tumors with an estimated incidence of 
81 00 in soft tissue and 2500 in bones and joints per year in the USA\ and 
approximately 5000 cases per year in Europe. Just over 50% of these patients 
will eventually die of the disease. 
In general sarcomas do not originate from preexisting benign lesions unlike 
typical carcinoma progression. In that respect sarcomas are more similar to the 
de novo high-grade carcinomas. Gaining a thorough understanding of these 
disease entities is extremely difficult due to the low incidence and the great 
diversity in histopathologic presentation, anatomic site, and biologic behavior. It is 
nevertheless clear that most soft tissue sarcomas are curable when diagnosed at 
an early stage2. The major predictive parameters of regional control are size and 
location of the primary lesion, pathological grading, previous treatments and 
quality of surgical margins. When diagnosed at the time of extensive local or 
metastatic disease, soft tissue sarcomas are rarely curable. In spite of their 
diversity in· histopathologic characteristics, the different types of sarcoma have 
many clinical and pathologic features in common. They are characterized by local 
invasiveness and the pattern of metastasis of most sarcomas is hematogenous, 
lymph node metastasis being uncommon. The clinical behavior of most types of 
sarcoma is also similar, determined more by anatomic localization, grade and 
size than by histologic markings. 
MANAGEMENT OF SOFT TISSUE SARCOMA 
The fundamental treatment for all soft tissue sarcomas of the extremity and trunk 
is surgical excision3.4. Controversy exists on how extensive that surgical excision 
should be and on whether it should be preceded or succeeded by adjuvant 
therapy5. Radiation therapy is generally used as a surgical adjuvant. External 
beam radiation has been the most commonly applied treatment, although there is 
an increasing interest in adjuvant brachytherap/·7 . Radiation therapy can also be 
delivered in preoperative fashion8 . Radiation alone is rarely used for unresectable 
tumors or for a medically inoperable patient. 
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To explore the role of adjuvant chemotherapy many randomized studies with 
different regiments of chemotherapeutics have been conducted9-13 . A large 
number of these trials showed no detectable difference in outcome; some 
showed an advantage in disease-free survival, but no difference in overall 
survival14-17. Doxorubicin and Ifosfamide are the two most active agents 18-20 . As 
could be expected, these adjuvant therapies were associated with 
myelosuppression and neutropenic fever and toxic deaths from infection or heart 
failure were occasionally encountered. To overcome these problems different 
routes of administration have been pursued. Improvements in the efficacy of 
medical treatments for soft tissue sarcomas may derive from old strategies by 
aiming to counteract the side effects of standard chemotherapy regimes and from 
new, less toxic, anticancer drugs. 
ISOLATED LIMB PERFUSION; COMBINATION THERAPY 
The technique of isolated limb perfusion (ILP) was first described by Creech eta/. 
in 1958 at the Tulane University of New Orleans. It was used for the treatment of 
a patient with multiple in-transit metastasis of a melanoma, who refused 
amputation21 • A complete response and thus limb salvage was achieved using 
melphalan in an extra corporeal circulation system. With this technique isolation 
of the blood circuit of a limb is achieved by clamping the major artery and vein, by 
ligating the collateral vessels, and by applying a tourniquet around the base of 
the limb to compress the remaining minor vessels in the muscles, subcutaneous 
tissues, and skin. After cannulation of the vessels, the isolated extremity is 
provided with an artificial circulation by means of an oxygenated extra corporeal 
circuit, into which cytostatic drugs can be administered. This way high local 
concentrations of the drug can be established, with an opportunity to apply local 
heat to improve the local uptake of the drug by tumor cells22•23 • After the perfusion 
a washout procedure is performed to ensure no systemic exposure to the active 
substance used. 
The advantage of this treatment modality is found in the fact that high local drug 
concentrations can be established while systemic side effects of high toxic doses 
can be avoided. Regarding soft tissue sarcoma, numerous combinations of 
cytostatic drugs have been utilized24. Isolated limb perfusion with cytostatic drugs 
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alone uniformly failed because these large soft tissue sarcomas showed a lack of 
response. This is in contrast to the usually small in transit-melanoma metastases 
for which an ILP with melphalan alone results in complete response rates in 
approximately 50% of patients, with an additional 25-30% of patients showing 
partial responses25•26. The application of Tumor Necrosis Factor (TNF) in 
combination with melphalan in the setting of ILP would completely change the 
situation for soft tissue sarcomas. Eggermont et at. used a combination regimen 
consisting of TNF, interferon gamma (IFN) and melphalan, which resulted in 
major tumor responses in 82 to 87% of all patients27,28 . Moreover this rendered 
these large sarcomas resectable in most cases and limb salvage could be 
achieved in 82 to 84%. Although in melanoma the administration of melphalan 
alone is effective to reach adequate response rates, in soft tissue sarcoma TNF 
needs to be added too in order to achieve this. The synergizing role between 
TNF and IFN did not prove to be of benefit in these series, which eventuated in 
the continuation of the treatment with TNF and melphalan29. 
TUMOR NECROSIS FACTOR 
TNF belongs to the family of cytokines, and is predominantly produced by 
activated cells of the immune system (monocytes, macrophages, natural killer 
cells, B-cells and T-cells). Many years went by since the observation of 
spontaneous regression of cancer in patients with a concurrent bacterial infection 
in 1891 by Coley30 . It was not until 1975 that a factor causing hemorrhagic 
necrosis in experimental tumors, later named Tumor Necrosis Factor-a, was 
discovered by Carswell31 and Old32. It took almost a century (in 1984) before the 
protein was isolated and eDNA was cloned, by Pennica and co-workers33. It 
turned out to be a 17kDa glycoprotein, which consists of 3 molecules. This tri-mer 
is the biologically active form of TNF and binds to the membrane-bound TNF 
receptor complex. Two well-defined receptors belong to this complex: a 55 kDa 
TNF-R1 and a 75 kDa TNF-R2 receptor34. Biological activity mediated by these 
two receptors is different, leading to cytotoxicity, apoptosis and fibroblast 
proliferation by TNF-R1, while T-and B-cell proliferation is predominantly 
mediated by activation of TNF-R235. 
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TNF is released systemically in small amounts when the healthy immune system 
is triggered, leading to inflammation, fever, and an acute phase reaction thus 
protecting the individual from possible pathogens. Systemic TNF in large 
quantities may activate neutrophils, modify the anticoagulant properties of 
endothelial cells and induce the release of other inflammatory cytokines such as 
IL-6, IL-8 or IL-1 !3 resulting in cardiovascular collapse, sepsis or shock. Locally 
administered high doses of TNF (e.g. by means of ILP) however mainly target the 
tumor associated vasculature, resulting in upregulation of endothelial adhesion 
molecules, a marked hyper permeability, platelet aggregation and hemorrhagic 
necrosis due to selective occlusion of the nee-vasculature. 
The vasodilatation of tumor vessels and changes in perfusion patterns and 
vascular permeability enhances significantly drug uptake of cytostatic agents into 
the tumor36•37 resulting in synergistic antitumor effects. Melphalan, an alkylating 
cytostatic that will interfere with mitosis and cell division in replicating cells 
irrespective of cycle stage, is an ideal cytotoxic agent for the ILP setting. 
ANGIOGENESIS; BALANCE IN CYTOKINES 
The interactions between malignant cells and the surrounding tissue are complex 
and involve a large variety of mechanisms and factors. Tumors exert an effect on 
tumor stroma and potential on newly formed tumor vasculature using a complex 
web of signals that they can secrete consisting of interleukins, CAM's (cellular 
adhesion molecules), cytokines, integrines, proteases and receptors. Many 
studies by Folkman for instance have produced evidence that tumor growth is 
dependent on the capability to already form neovasculature in an early stadium38. 
Without this capability a tumor will not be able to grow over 0.2 mm in diameter in 
mice lung metastases, till a maximum of 2 mm diameter in case of avascular 
chondrosarcoma in a rat. The lethal power of a tumor, which is determined by the 
pace of growth and metastasis velocity, is also dependent on neovascularisation. 
Successful angiogenesis requires an increased permeability of the basal 
membrane and a migration of endothelium cells in one defined direction. Also 
formation of peri-endothelial stroma needs to take place. A fast expanding list of 
pro- and antiangiogenic factors secreted by tumors can serve as a proof that 
tumors themselves are responsible for this process of angiogenesis in their 
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environmene9• 40 . An extensive group of cytokine~ belongs to this list41 and these 
may play a crucial role in the future of combined anticancer strategies. 
ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II 
Infusing TNF into mice-bearing methylcholantrene .A-induced (MethA) 
fibrosarcomas causes rapid induction of intravascular coagulation at the tumor 
site, resulting in a major drop in tumor blood flow. In this model that is used to 
study host-tumor interactions, the MethA tumor shows a rapid induction of 
thrombohemorrhage resulting in hemorrhagic necrosis and subsequent tumor 
regression after treatment with TNF. Since this feature did not appear in other 
mice tumors it was hypothesized that tumor-derived factors produced by this 
MethA tumor made this tumor more likely to respond to TNF with thrombotic 
events42 . A number of polypeptides have been isolated from its supernatant, 
including a 44-kDa polypeptide endothelial monocyte activating polypeptide I 
(EMAP I) and the 22-kDa EMAP 1143 , the latter being the most potent of all 
polypeptides found. EMAP II was named after just one of its many effects since it 
influences also endothelial cells, neutrophils, and monocytes44. 
It has also been shown that EMAP II enhances the induction of the procoagulant 
tissue factor (TF) on endothelial cells44, and is able to increase the cellular 
receptors for TNF on endothelial cells, which is likely to enhance the 
predisposition of tumors to undergo thrombosis and hemorrhagic necrosis once 
challenged with TNF45 . Wu et a/. demonstrated that this constitutive over-
expression of EMAP II in a TNF-resistant melanoma cell line by retroviral-
mediated transfer of EMAP II eDNA rendered this tumor sensitive to the effects of 
systemic TNF46•47 . This feature sparked our recent interest in this new cytokine. 
CLINICAL IMPLICATIONS 
The characteristic of EMAP II to sensitize tumors for the impact of TNF implies a 
promising improvement of TNF treatment in patients with disseminated disease. 
Moreover, recent studies also demonstrate an antiangiogenic effect of EMAP II 
by inhibiting corneal neovascularisation in mice48 and by preventing vessel 
outgrowth in a rat aortic ring assal9. 
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This data suggests an important role of EMAP II in the treatment against cancer. 
Not only will EMAP II enhance the effect that TNF exerts on certain tumor types, 
it can also play a role in maintaining dormancy of tumor outgrowth by preventing 
vessel formation. 
If the level of EMAP II expression in a tumor can be determined before TNF 
treatment is started, a response can be predicted and maybe even improved by 
upregulating the EMAP II expression. In the group of patients with a low EMAP II 
expressing tumor the perfusion could be preceded by a therapy to upregulate 
EMAP II, for instance by gene therapy as has been demonstrated in mice with a 
recombinant Vaccinia virus encoding the human EMAP II gene45. 
EMAP II has the potential to become a potent anticancer agent since it can 
contribute in several important ways: diminishing local toxicity of TNF making a 
lower dose sufficient, improving anticancer effects, preventing formation of 
metastasis by the antiangiogenic effect and predicting outcome of TNF based 
therapy. Resistance to EMAP II is unlikely as its effects are mainly at endothelial 
cell level, which is a constantly renewing vessel lining. Tumors will be destructed 
after EMAP 11-mediated sensitization to the vasotoxic effects of TNF in 
combination with chemotoxic agents. 
AIM OF THE THESIS 
The aim of this thesis is to gain greater insight into how TNF produces its effect in 
current cancer treatment with the overall goal of improving TNF-based cancer 
treatment. TNF response as well as toxicity takes place at the vascular level 
where cytokines can have effect on the endothelial cells. We describe matters 
concerning this interaction as well as related experiments that have been 
conducted in our laboratory. 
Chapter 2 gives the results of a clinical trial in which we investigated if TNF 
based perfusion has additional toxic effect in humans, and if so, how much 
damage this evoked in the treated patient. In a unique setting we had the 
opportunity to compare two groups of patients. One group received a hepatic 
perfusion with TNF, the other group received a similar perfusion but without TNF. 
Clinical and pharmacologic results are presented of this retrospective study. 
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Since it is known that TNF exerts its effect on the tumor vasculature, one could 
speculate on the response rates in highly vascularized tumors. In chapter 3 data 
of limb perfusions with TNF and melphalan in highly vascularized Stewart Treves 
angiosarcoma is presented. In a retrospective study clinical records of 10 patients 
with Stewart Treves angiosarcoma were reviewed. 
Since radiotherapy influences vascularisation in the radiated field, we conducted 
a study in a group of patients who received radiotherapy for their primary tumor 
and we are now experiencing a relapse of their disease. In chapter 4 we 
demonstrate that it is possible to perform perfusion in radiated tissue, and clinical 
data and response rates are presented. These clinical observations raise 
questions about the antitumor effect of TNF. 
In chapter 5 we demonstrate that TNF is the agent responsible for the increased 
intratumoral melphalan concentration in isolated perfusions with TNF and 
melphalan in a liver perfusion model performed in rats. When TNF was left out of 
the perfusate a 4- to 6-fold lower intratumoral melphalan concentration was 
measured. 
On the cellular level improvement of the TNF response is pursued in chapter 6. 
EMAP II increases cellular receptors for TNF on endothelial cells, this feature 
enables EMAP II to confer TNF sensitivity of TNF-resistant tumors. In our lab we 
retrovirally transduced a rat soft tissue sarcoma with the EMAP II gene in order to 
create a tumor with an up regulated EMAP II expression. This tumor was injected 
into rats that received a TNF-based ILP after 10 days. 
Chapter 7 describes experiments with the chemokine Interferon-inducible 
Protein-10, IP-10, which has antiangiogenic properties in vivo. In our study we 
evaluate the effects of retroviral IP-1 0 gene delivery and protein expression on 
human melanoma xenografts in nude mice. We expect that inhibition of tumor 
angiogenesis reduces the growth rate of the tumor. 
In chapter 8 contemporary experiments and current controversies regarding 
EMAP II are reviewed. Considering our own experiments we describe the 
predictive value of EMAP II in patients with sarcoma and the problems that must 
be solved to achieve this. EMAP II is likely to be of importance in developing new 
approaches aimed at improving the efficacy of the use of TNF as an anticancer 
treatment. Finally, in chapter 9, the conclusions are summarized. 
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Role of TNF on toxicity and cytokine production 
ABSTRACT 
Introduction: Isolated limb (ILP) or liver perfusion (IHP) with tumor necrosis 
factor (TNF) and melphalan results in regression of advanced cancers in the 
majority of treated patients. However, the contribution of TNF to the efficacy of 
isolation perfusion with melphalan has not been conclusively demonstrated in 
random assignment trials. Furthermore, TNF is an inflammatory cytokine and 
may be associated with significant systemic and regional toxicity. This study was 
conducted to characterize the toxicity and secondary cytokine production 
attributable to TNF by comparing these parameters in patients undergoing IHP 
using melphalan with or without TNF. 
Methods: Thirty-two patients with unresectable colorectal cancer confined to the 
liver underwent a 60-minute hyperthermic IHP using 1.5 mg/kg melphalan alone 
(n=17) or with 1.0 mg of TNF (n=15). Post-IHP parameters of hepatic and 
systemic toxicity and cytokine levels (TNF, IL-6 and IL-8) in perfusate and serum 
were measured. 
Results: Levels of IL-6 and IL-8 in perfusate at the end of the 60 minute IHP 
were significantly higher in TNF treated patients. Peak systemic IL-6 and IL-8 
levels post-IHP were also significantly higher in TNF treated compared to non-
TNF treated patients by 28 and 268 fold, respectively. The peak levels of these 
cytokines were associated with significantly lower systolic blood pressure and 
higher heart rate and mean pulmonary artery blood pressure in TNF treated 
patients during the first 48 h post-IHP. Serum bilirubin levels were significantly 
higher and platelets lower in TNF treated compared to non-TNF treated patients. 
However, elevations in AST, AL T, and alkaline phosphatase were not 
significantly different between groups and returned towards baseline within 1 
week after IHP. 
Conclusions: Addition of TNF to melphalan during IHP results in significant 
differences in post-IHP production of IL-6 and IL-8 with associated changes in 
mean arterial blood pressure and greater regional toxicity as reflected in higher 
levels of serum bilirubin. However, these measurable differences were transient 
and did not appear to be of major clinical consequence. The benefit of TNF in 
isolation perfusion should be demonstrated in random assignment trials prior to 
its routine use. 
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INTRODUCTION 
TNF, a secreted 17 kD protein with a range of physiological activities, was 
originally identified in the sera of bacillus Calmette-Guerin (BCG)-primed 
endotoxin-treated mice as a circulating factor resulting in remarkable 
hemorrhagic necrosis of tumors When administered to tumor bearing mice 1. After 
it became available in recombinant form a number of clinical trials were 
performed with the expectation that it could produce similar results in patients 
with advanced cancer. However, it was shown that humans are exceedingly 
sensitive to the toxic effects of TNF and at the maximum tolerated systemic 
doses there was no meaningful antitumor activit/. Furthermore, there was 
contemporaneous evidence that TNF was the primary endogenous mediator of 
acute inflammatory conditions such as endotoxic shock and it appeared that 
inhibiting its effects might have broader clinical application than the protein 
itself3.4. 
However, in 1992 Drs. Lienard and Lejeune reported their initial experience using 
TNF in isolated limb perfusion in combination with melphalan, interferon, and 
hyperthermia for in transit extremity melanoma or high grade unresectable 
extremity sarcoma5. The complete response rate in 29 evaluable patients was 
90% and rekindled considerable interest in the use of TNF with melphalan in 
isolation perfusion. Subsequent reports have confirmed complete response rates 
of greater than 78% after ILP for patients with in transit extremity melanoma, a 
limb salvage rate of 84% for patients with unresectable high grade extremity 
sarcoma, and an overall response rate of 74% in patients with unresectable 
hepatic malignancies treated with isolated hepatic perfusion6-8 . However, no 
reports have conclusively established a benefit of adding TNF to melphalan 
compared to melphalan alone in isolation perfusion. A single small prospective 
random assignment trial of ILP with melphalan, TNF, and IFN, compared with 
melphalan alone, showed no difference in overall or complete response rates 
between groups9. During ILP with TNF a perfusate leak of less than 5% into the 
systemic circulation is associated with significant hemodynamic effects, primarily 
hypotension 10•11 . 
Recently various institutions have reported results using TNF and melphalan in 
IHP, with large variations in antitumor response as well as toxicit/;12-14. This 
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study characterizes the profile of inflammatory cytokine production (IL-6 and IL-8) 
and regional and systemic toxicities observed in a cohort of patients with 
metastatic unresectable adenocarcinoma of the colon confined to liver who 
underwent IHP with or without TNF and had otherwise identical treatment 
parameters. Moreover, because all patients had complete vascular isolation of 
the liver with no measurable leak of perfusate, differences between groups are 
not confounded by systemic exposure to the TNF or melphalan. 
PATIENTS AND METHODS 
Patient Population 
Between March 1996 and November 1998, 32 patients were treated with a 60 
minute hyperthermic IHP. In 15 patients the combination of TNF (1.0 mg) and 
melphalan (1.5 mg/kg) was given and in 17 patients melphalan alone (1.5 mg/kg) 
was used. The protocols were approved by the Institutional Review Board and 
the Cancer Therapy Evaluation Program (for the use of TNF) of the National 
Cancer Institute. Patients were treated on 2 consecutive Phase II protocols using 
identical IHP treatment parameters; the latter without TNF. All patients had 
unresectable biopsy-proven bilobar metastatic colorectal cancer confined to the 
liver. Standard staging studies including computed tomography scan of the chest, 
abdomen and pelvis, magnetic resonance imaging of the liver and, when clinically 
indicated, brain imaging or bone scan were performed. Eligibility criteria included 
Eastern Cooperative Oncology Group performance status of 0 or 1, a serum 
bilirubin <2.0 mg/dl, a platelet count >150,000 /ml, and a serum creatinine <1.5 
mg/dl. All patients were evaluated 6 weeks after treatment and at 3 to 4 month 
intervals thereafter. Responses were scored by comparing gadolinium-enhanced 
T-1 weighted images on MRI scans during follow-up with pre-treatment images. 
All lesions were measured and a partial response was defined as a reduction of 
50% or greater in the product of the perpendicular diameters of the lesions on 
MRI for a period of at least one month without the development of new lesions or 
progression of existing lesions. 
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/HP 
The technique of IHP was performed as described previousl/·15. Briefly, via a 
laparotomy the liver is extensively mobilized by dividing the falciform ligament 
and the right and left triangular ligaments. The duodenum is mobilized and 
reflected medially to expose the inferior vena cava (IVC). The right lobe of the 
liver is reflected anteriorly and medially and the IVC from the level of the renal 
veins to the diaphragm is completely dissected from the retroperitoneum. The 
porta hepatis structures are completely dissected and skeletonized and a 
cholecystectomy is performed. A 2 em segment of the gastroduodenal artery 
(GOA) is dissected and serves as the arterial cannulation site during IHP. The 
portal vein and common bile duct are dissected from the head of the pancreas to 
the inferior border of the liver. All lymph node-bearing tissues around the porta 
hepatis structures are resected. A saphenous vein and left axillary cutdown are 
performed. 
The patient is systemically heparinized with 200 units/kg and after 5 minutes a 
cannula is inserted into the saphenous vein and advanced into the IVC just below 
the renal veins. A second venous cannula is inserted into the axillary vein and 
both are connected to a veno-veno bypass circuit. The IVC is occluded above the 
renal veins and infra hepatic IVC blood flow is shunted to the axillary vein using a 
centrifugal pump. A short segment of infra hepatic IVC is isolated between 
vascular occluding clamps and a 20-24 French cannula is inserted through a 
venotomy and positioned behind the retrohepatic IVC just beneath the hepatic 
veins. This cannula is connected to the venous outflow line of the extra corporeal 
bypass circuit. A cannula is positioned in the portal vein and connected to the 
veno-veno bypass circuit to shunt portal vein blood flow systemically. The GOA is 
ligated, the common hepatic artery is occluded and a 3-4 mm GOA cannula is 
positioned at the orifice of the common hepatic artery. Finally, the supra hepatic 
IVC is cross-clamped just below the diaphragm and isolated hepatic perfusion is 
initiated. 
The extra corporeal bypass circuit consists of a roller pump, membrane 
oxygenator, and heat exchanger. The perfusate consists of 700 ml of balanced 
salt solution primed with 300 ml of packed red blood cells and 2000 units of 
heparin. Arterial and venous perfusate blood gases are obtained at regular 
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intervals and arterial perfusate pH is maintained between 7.2 and 7.3 with sodium 
bicarbonate. Hepatic parenchymal temperature probes are placed and perfusate 
warmed using a Hematherm water heater model #4 (Cincinnati SubZero 
Products, Cincinnati, Ohio). Flow rates are adjusted upward while monitoring for 
a stable reservoir volume and acceptable line pressures. There is typically rapid 
and uniform heating of the liver to target temperatures of 39.5 to 40°C. 
Melphalan, 1.5 mg/kg with or without TNF, 1.0 mg, are added sequentially to the 
arterial inflow line of the perfusion circuit at time 0 and IHP continued for 60 
minutes. At the conclusion of IHP, the liver is flushed through the arterial inflow 
cannula with 1500 ml of crystalloid followed by 1500 ml of colloid and through the 
portal vein with 1 liter of normal saline. After decannulation and repair of the IVC 
and portal venotomies, normal physiological blood flow is reestablished promptly 
to the liver. 
Drugs 
Melphalan was obtained from Glaxo-Wellcome, Research Triangle Park, NC and 
recombinant human TNF from Knoll Pharmaceuticals, Whippany, NJ. 
Blood sampling and Hemodynamic Monitoring 
Perfusate was sampled at time 0, 15, 30 and 60 min during IHP. Blood samples 
were obtained at regular intervals beginning before and after IHP for clinical 
laboratory parameters; serum samples for cytokine determination were collected 
at the same intervals as perfusate samples during IHP and at regular intervals for 
24 hours after IHP. Hemodynamic, pulmonary and other systemic endpoints were 
measured at intervals as clinically indicated but no less than every 8 hours after 
IHP for up to 60 hours. 
Cytokine assays 
All blood and perfusate samples for cytokine determination were immediately 
refrigerated and serum separated and frozen until analyzed. TNF, IL-6 and IL-8 in 
perfusate and serum were measured by an enzyme linked immunosorbent assay 
(ELISA) using the Quantikine Immunoassay kits (R&D Systems Inc.). In these 
assays monoclonal antibodies raised against the cytokines were used according 
to procedures similar to those described earlier. Results for IL-6 and IL-8 are 
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expressed as picogram per milliliter; the lower limit of detection was 0.0312 
ng/ml. Results for TNF are expressed as microgram per milliliter; the lower 
detection limit for the assay was 0.016 ng/ml. 
Statistical analysis 
Values are expressed as mean ± standard error of the mean (SEM). For the 
regional toxicity variables, a Wilcoxon rank sum test was performed on the data 
collected one day before IHP to determine whether the two groups were the 
same at baseline. AST, AL T alkaline phosphatase and systemic vascular 
resistance were log1 0 transformed and serum bilirubin levels were square root 
transformed to reduce skewness in distributions. A repeated measured analysis 
of variance (ANOVA) was then performed on each variable starting with time 0. 
To account for correlation between repeated measurements, we tested 
autoregressive, heterogeneous autoregressive, and Toeplitz covariance matrices 
for each variable and chose the best fitting matrix according to Schwarz's 
Information Criteria 16. For variables in which the interaction term was significant, 
the p values from the combined test of the treatment effects over time is reported. 
The assumption of normally distributed residuals was satisfied. P values p<0.05 
were considered to be statistically significant. 
RESULTS 
Patient demographics and tumor characteristics are shown in Table 1. 
Table 1 - Patient demographics and tumor characteristics 
N 
Male: Female 
Age (years) 
Mean 
Range 
Previous treatment(%) 
Median no. metastases (range) 
Size largest lesion (em)* 
Median PHR 
Pre-operative CEA level 
(mean±SD in ng/ml)* . 
*p>0.3, unpaired t-test 
PHR= percent hepatic replacement 
Total 
32 
22:10 
54.5±2.2 
25-74 
23 (72%) 
TNF 
15 
9:6 
51.1±3.5 
25-72 
10 (67%) 
6 (2-38) 
9.1±4.1 
25 (10-70) 
603±722 
NoTNF 
17 
13:4 
57.4±2.6 
33-74 
13 (76%) 
6 (1-19) 
8.2±4.7 
20 (5-65) 
1479±3316 
There was a similar mean age, a roughly 2:1 male/female ratio and the percent of 
patients who had been previously treated was comparable between groups. In 
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addition, the tumor burden, as reflected by number of liver metastases, size of 
largest lesion, percent hepatic replacement, and pre-operative CEA level were 
similar between groups. The overall radiographic response rate was 72% and not 
different between those receiving and not receiving TNF (Table 1 ). Fifteen 
patients were treated with a 60-minute hyperthermic IHP using 1.5 mg/kg 
melphalan; seventeen patients also received 1 mg of TNF. IHP perfusion 
parameters are listed in Table 2. 
Table 2: IHP parameters 
Total TNF NoTNF 
n 32 15 17 
Melphalan dose 
Mean (mg) 109.3±2.0 110±3.7 108.5±2.1 
Range (mg) 90-130 90-130 92-122 
Duration (min) 60 60 60 
Flow rate 
Mean (ml/min) 882.3±24.6 833.7±27.0 925.3±37.3 
Range (ml/min) 600-1350 600-1050 650-1350 
pH perfusate 
Mean 7.21±0.03 7.18±0.04 7.23±0.05 
Range 6.92-7.64 6.92-7.51 6.96-7.64 
Mean central hepatic T (°C) 40.0±0.04 39.9±0.04 40.0±0.06 
Mean perfusion pressure (mm Hg) 162.3±5.3 160.1±9.0 164.2±6.3 
Perfusion pressure Range (mm Hg) 103-240 103-240 120-202 
Mean change reservoir volume (ml) 64.8±13.4 96.7±22.5 36.6±12.7 
All parameters were comparable between the two groups except for flow rate that 
was higher, but not significantly (p = 0.06) in the no TNF group. The reason for 
this is not clear and not due to any bias or attempt to achieve higher flow rates in 
patients not receiving TNF. Because there was no difference in the pH of the 
perfusate between groups, we presume that the differences in flow rates were 
physiologically inconsequential and did not influence hepatic toxicity. Using a 
radiolabeled 1-131 albumin continuous leak monitoring system, there was no 
identifiable leakage of perfusate into the circulation in any patient. Because of the 
unique vascular anatomy of the liver it our experience that complete vascular 
isolation with no leak of perfusate can be routinely achieved during IHP8. This is 
further supported by the fact that the mean change in reservoir volume in each 
group was minimal, less than 100 ml, indicating no leak of systemic blood into 
the perfusion circuit. Small changes in reservoir volume that occur during IHP 
most likely reflect changes in passive filling or emptying of the hepatic vascular 
bed. 
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A number of hemodynamic parameters were compared between groups during 
the first 48 hours after IHP. There were no significant differences in systemic 
vascular resistance, cardiac output or temperature. However, patients who 
received TNF had a significantly higher mean heart rate, lower systolic blood 
pressure and higher peak mean pulmonary artery blood pressure compared to 
melphalan alone (Figure 1 ). However these differences were gone by 48 to 60 
hours and did not appear to be of major clinical consequence. Hypotension was 
treated with fluid resuscitation and no patient in the TNF group required 
circulatory support with cardiopressor agents. 
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Figure 1 Mean heart rate, peak pulmonary artery pressure, and 
systolic blood pressure in patients following IHP with (n=15) or 
without (n=17) TNF. In patients receiving TNF heart rate (p<0.03) 
and peak mean pulmonary artery pressure (p=0.033) were higher 
and systolic blood pressure lower (p<0.01 at 0 and 8 hours and 
p<0.05 at 40 hours) in patients receiving TNF compared to those 
that did not. 
In patients receiving TNF initial mean perfusate levels determined 15 minutes 
after beginning IHP were 637±333 1-Jg/ml and decreased to 520±185 1-Jg/ml at 
the end of IHP consistent with our previously reported findings 17. Perfusate IL-6 
and IL-8 levels are shown in Figure 2. 
Baseline levels of each cytokine were comparable between groups and 
significantly higher after IHP in the TNF group compared to melphalan alone. In 
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patients receiving TNF, systemic levels were consistently measurable only at 1.5 
hours after IHP (7.5±20 j..lg/ml, range: 1- 83) whereas in those not receiving TNF 
there was no detectable systemic TNF in any sample at any time point after IHP. 
Systemic IL-6 and IL-8 levels are shown in Table 3. 
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Figure 2 Mean IL-6 and IL-8 levels in perfusate during IHP in 
patients treated with (n=15) or without (n=17) TNF. Perfusate 
cytokine levels were significantly higher in those treated with TNF 
(p<0.0001 ). 
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Table 3 -Systemic cytokine concentrations starting immediately after IHP 
a. Serum IL-6 (pg/ml) 
With TNF 
Range 
NoTNF 
Range 
b. Serum IL-8 (pg/ml) 
0 hours after IHP* 
312±43 
60-670 
287±31 
44-451 
4-6 hours 
23543±4144 
4661-60033 
841±335 
96-4763 
With TNF 250±73 7333±1113 
Range 48-1190 672-12492 
No TNF 65±13 274±42 
Range 23-195 71-580 
*Time starting just after IHP when native blood flow to liver had been established. 
24 hours 
478±95 
15-1312 
264±77 
31-1035 
53±14 
9-221 
52±7 
22-112. 
Time 0 represents the time immediately after IHP just after the native hepatic 
vascular blood flow had been re-established. In patients receiving TNF, serum 
levels of IL-6 increased rapidly to a peak value of 23543±4144 pg/ml and IL-8 
increased to 7333±1113 pg/ml between 4 to 6 hours after I HP and returned 
towards baseline within 24 hours. The peak systemic levels of cytokines were 
significantly correlated (Spearman rank correlation coefficient r=0.68, p=0.006). 
The peak values were significantly greater than those observed with melphalan 
alone and occurred coincident with the maximum changes in systolic blood 
pressure. 
All patients had significant elevations in AST and AL T that returned towards 
baseline within the first week after IHP as previously reported for patients 
undergoing IHP with melphalan and TNF8. However, after IHP there is a transient 
marked elevation in serum bilirubin in patients receiving TNF that was not 
observed in those receiving melphalan alone (Figure 3). 
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Figure 3 Mean platelet count and serum bilirubin levels in patients 
following IHP with (n=15) or without (n = 17) TNF. Platelet levels 
were significantly lower in patients treated with TNF on days 4 
through 7 (p<0.05) and serum bilirubin levels averaged over days 1 
through 7 were significantly higher (p=0.017) in patients receiving 
TNF compared to those that did not. There were no differences in 
baseline values between groups 
Platelets decreased after perfusion with a significant difference observed 
between the groups after day 3. However, in both groups the level of 
thrombocytopenia did not require any intervention and started to normalize after 
one week. Mean pre-IHP creatinine levels were significantly different (p=0.002) 
for reasons that are not clear. Creatinine levels were not different between 
groups after IHP following correction for differences in baseline levels. There 
were no differences in post-IHP alkaline phosphatase, white blood cell count or 
prothrombin time. 
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DISCUSSION 
The data presented in this study show that in patients undergoing IHP with 
virtually all major treatment variables equal and without any measurable leak of 
perfusate into the systemic circulation, the addition of TNF to melphalan in the 
perfusate is associated with significant regional and systemic toxicity compared 
to those receiving melphalan alone. Interestingly, the significantly lower mean 
systolic blood pressure in patients treated with TNF was coincident with 
significantly higher peak levels of IL-6 and IL-8 occurring 3 to 4 hours after IHP. 
Other studies have reported systemic toxicities associated with the use of TNF in 
ILP or IHP that were due largely, if not exclusively, to systemic exposure of TNF 
secondary to perfusate leak during treatment10·14•18•19. Thom et a/. 10 observed that 
patients experiencing a perfusate leak of greater than 1% during ILP with TNF 
and melphalan had significantly greater systemic toxicity associated with higher 
circulating levels of IL-6 and IL-8. Activation of the fibrinolytic system as reflected 
by significant increases in circulating tissue plasminogen activator activity has 
been observed following systemic TNF leak in ILP patients 19. Similarly, increases 
in circulating levels of the soluble TNF receptor are observed following systemic 
TNF leak during ILP in amounts proportional to the serum TNF up to levels of 1.5 
ng/ml. TNF induced hypotension appears to occur when the capacity of released 
soluble TNF receptors to neutralize circulating TNF levels is exceeded. Under 
conditions in which serum TNF levels are considerably greater than 1.5 ng/ml 
following ILP, refractory hypotension with associated hematological, hepatic and 
pulmonary toxicities can occut'0•21 . Lidner et a/. 18 reported considerable toxicity 
when performing IHP with melphalan and 30 to 200 !Jg of TNF which resulted in a 
22% mortality that was most likely due to systemic exposure of TNF and 
melphalan. These previous data highlight the importance of controlling perfusate 
leak of TNF during isolation perfusion. The data in this study are consistent with a 
previous report of 6 patients undergoing IHP using melphalan with or without 
TNF22. In that study data from 3 patients who received 0.4 mg of TNF and 1 
mg/kg of melphalan and 3 patients who received melphalan alone showed that 
systemic TNF levels peaked soon after IHP in the former group and were not 
detectable in the latter. In addition, perfusate levels of IL-6 increased during IHP 
only in those receiving TNF and systemic levels were significantly higher between 
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2 and 9 hours after IHP compared to those who received melphalan alone. The 
current study demonstrates that with complete vascular isolation of the liver and 
virtually all other treatment parameters equal, the production of secondary 
mediators in the liver after IHP with TNF and melphalan may result in subsequent 
transient hemodynamic alterations not observed with melphalan alone. 
IL-6 and IL-8 are inflammatory cytokines with known effects on the cardiovascular 
system23-26; whether they are the direct cause of the relatively greater degree of 
hypotension following IHP in this study is not known. Of note, the differences in 
blood pressure between those who did or did not receive TNF were clearly 
transient and did not appear to be a major clinical consequence. No patient 
treated with TNF required cardiopressor support because of hypotension. 
Elevated plasma levels of IL-6 have been reported in patients with sepsis and 
shown to correlate with heart rate, hypotension, thrombocytopenia, and death23; 
24
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. The mean peak systemic IL-6 level in patients treated with TNF and IHP 
was over 23,000 pg/ml (maximum > 60,000 pg/ml) which is higher than the 
reported mean levels of patients in septic shock of approximately 10,000 
pg/mL23•24• Similarly, elevated plasma IL-8 levels have been reported in patients 
with sepsis and shown to correlate with hypotension and death25·28 . The mean 
peak systemic levels in TNF treated IHP patients (>7,000 pg/ml) is about 2-fold 
greater than plasma levels in patients with lethal septic shock. The correlation 
between systemic IL-6 and IL-8 levels in this study have also been observed in 
septic patients28. The fact that the high circulating levels of IL-6 and IL-8 
observed in this study were associated with only transient hemodynamic changes 
is most likely due to the limited and controlled exposure to TNF during IHP 
compared to septic individuals with uncontrolled bacteremia and ongoing 
cytokine production. Our data indicate that hepatic synthesis and release of pro-
inflammatory cytokines may be a major source of endogenous mediators during 
sepsis and that TNF can stimulate significant hepatic pro-inflammatory cytokine 
production clinically. 
Although there are limited clinical data, during ILP for in transit melanoma of the 
extremity, the use of TNF alone is associated with minimal regional toxicit/9 . 
However, because of the metabolic nature of the liver the use of TNF alone in 
IHP has significant toxic effects. In a previous phase I study of escalating dose 
TNF administered with 0.2 mg interferon-gamma via IHP, dose-limiting 
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coagulopathy was encountered at 2.0 mg of TNF and did not result in any 
meaningful antitumor activiti2. A subsequent phase I study of alternating dose 
escalations of TNF and melphalan was conducted15 and dose-limiting melphalan 
toxicity was observed at 2.0 mg/kg (renal and liver) and TNF toxicity at 1.5 mg 
(coagulopathy). The maximum safe-tolerated dose of 1.0 mg of TNF when used 
with melphalan in IHP determined in our clinical trials is considerably less than to 
3-4 mg dose used in ILP at various institutions and highlights the different tissue 
tolerances of the protein. In a previous phase II trial of IHP using TNF and 
melphalan significant transient elevations in hepatic transaminases and bilirubin 
levels were observed8. Hepatic failure from vena-occlusive disease (VOD) is a 
known complication of high dose chemotherapy with a grave prognosis 
manifested initially by progressive elevation in serum bilirubin followed by ascites 
and progressive liver failure30. Although serum bilirubin were significantly higher 
in patients treated with TNF in this series, there were no other clinical or 
laboratory indications of hepatic VOD in any patient treated in this cohort. Liver 
biopsies were not routinely obtained so the pathological changes responsible for 
the elevations in bilirubin are not known. However, because of the transient 
nature of the hyperbilirubinemia, it was presumed to be related more to 
cholestasis than VOD. 
In summary, the data in this study provide additional insights of the 
pathophysiology of TNF toxicity during isolation perfusion and suggest that the 
liver may be a significant source of proinflammatory cytokine production 
secondary to TNF. As in animal models of endotoxin or TNF-induced shock31 •32, 
strategies to neutralize the IL-6 or IL-8 may ameliorate the hemodynamic or other 
consequences of TNF when perfused directly into the liver or when systemic leak 
occurs during ILP with this protein. The data indicate that if there is clinical benefit 
in terms of efficacy that TNF can be safely administered in isolation perfusion. 
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Isolated perfusion in Stewart Treves patients 
ABSTRACT 
Introduction: Cutaneous Stewart Treves lymphangiosarcoma represent a rare 
group of tumors. They are characterized by a high grade of vascularisation and 
by localization in an extremity with iatrogenic or congenital lymphedema. The 
multifocality and the localization makes these tumors eligible for treatment with 
isolated limb perfusion (ILP). ILP with melphalan and Tumor Necrose Factor 
(TNF) is a safe and highly effective biochemotherapy procedure that can achieve 
limb salvage in 80% or more of all patients with non-resectable extremity soft 
tissue sarcoma or melanoma. 
Methods: Here we present the outcome of 16 ILPs with TNF plus melphalan in 
1 0 patients with the rare condition of multifocal Stewart Treves 
lymphangiosarcoma of the extremities. All patients would have been candidates 
for exarticulation of the extremity. 
Results: After ILP we observed an 87% overall response rate, 1 patient had a 
mixed response and 1 patient failed to respond to the therapy. In 9 perfusions 
(56%) a complete response (CR) was achieved and 5 perfusions (31%) resulted 
in a partial response (PR). Limb salvage was achieved in 8 patients (80%) with a 
mean follow-up duration of 34.8 (3-115+) months. Regional toxicity was limited 
and systemic toxicity minimal to moderate with no toxic deaths. 
Conclusions: Our results demonstrate that a combined treatment with 
melphalan and TNF can eventuate in good clinical response rates in patients with 
extensive disease who were candidates for amputation. This implies that with the 
ILP we have a new treatment option in the management of Stewart Treves 
angiosarcoma. 
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INTRODUCTION 
Sarcomas are malignant tumors arising from skeletal and extra skeletal 
connective tissues. The cellular elements of these anatomic structures are 
diverse and as a consequence so is the natural history of both bone and soft 
tissue sarcomas. Soft tissue sarcomas (STS) have been classified 
histogenetically according to their morphological resemblance to normal 
congenate tissues. The best predictor of STS development is the grade, a 
measure of differentiation and aggressivity. In Europe, the incidence of STS is 
approximately 5000 cases per year. Little over 50% of these new patients will 
eventually die of the disease. Most STS do not have a clearly defined etiology 
and a great diversity of histopathologic presentation, anatomic site, and biologic 
behavior exists. 
Angiosarcomas constitute one of the many categories of STS. The generic term 
'angiosarcoma' includes the histologic subtypes of sarcoma originating from 
either lymphatic or capillary endothelium, comprising lymphangiosarcoma and 
haemangiosarcoma respectively. Together these lesions account for 
approximately 4% of all STS. In this report we limit ourselves to one histological 
type of highly vascularised sarcoma with lymphedema of the extremity as the 
common etiologic cause. 
Lymphedema has long been an established factor in the multifocal development 
of lymphangiosarcoma. In 1906, Lowenstein was the first to report this entity in a 
patient with chronic post-traumatic upper extremity lymphedema. It was not until 
Stewart and Treves in 1948 described the syndrome of multifocal 
lymphangiosarcoma 1, which carries their name, that this feature became more 
widely recognized. They described six cases of lymphangiosarcoma in 
chronically lymphedematous arms following radical mastectomy. Since their 
report over 300 cases have been reported in literature. This patient group will 
develop lymphangiosarcoma in edematous sites in the arm, with no correlation to 
areas that have been subjected to radiation therapl. Lymphangiosarcoma may 
also arise in a chronic and severely edematous extremity (elephantiasis), usually 
of congenital origin without a preceding tumor3-5, rarely in idiopathic lymphedema 
of delayed onset6•7, and even more rarely in chronic lymphedema secondary to 
the parasitic disease filariasis8•9 . Although the relative odds of 
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lymphangiosarcoma of the upper extremity following breast cancer are high, the 
absolute risk is low and estimated to be 0,001%10. 
Previous reports on the prognosis of lymphangiosarcoma in post mastectomy 
lymphedema are very poor. Sordillo et a/.11 report an overall survival 19 months 
after appearance of the first lesions of 50%, regardless of the type of therapy. 
The 5-year survival was as low as 13.6%. Management strategies of this 
multifocal disease so far have included amputation or exarticulation of the limb or 
limb sparing attempts utilizing radiation therapy and/or chemotherapi2 . 
With the introduction of the hyperthermic isolated limb perfusion (HILP) by 
Creech in 195813 a new technique was initiated to approach extremity 
malignancies. In 1992, Lienard et a/. 14 published their first report of the efficacy of 
ILP using TNF, melphalan and interferon gamma in patients with in transit 
metastasized melanoma in the extremity. Their promising results encouraged 
other investigators to use this treatment regimen, sparking the modern era of 
clinical TNF application. After disappointing results for the local treatment of STS 
with various chemotherapeutics, including the failure of treating locally advanced 
STS with ILP with melphalan alone 15, the combination of TNF and melphalan 
emerged as a very promising option for the limb-saving management of locally 
advanced STS16 . With this multi-drug approach a high response rate in patients 
with STS of the extremities was reached; an 82% limb salvage rate at a median 
follow-up of almost 2 years. We have demonstrated both in clinical17 and in 
experimental studies 18 that TNF in combination with melphalan in the setting of 
ILP exerts its antitumor effects primarily on the tumor-associated neovasculature 
with hardly any direct cytotoxic effect on cancer cells 19; 20 . This makes the group 
of patients with Stewart Treves angiosarcoma especially eligible to be treated 
with TNF based therapy. Here we report on our unique experience in addressing 
this. 
PATIENTS AND METHODS 
Patient Population 
Clinical records of 10 patients with Stewart Treves angiosarcoma were reviewed. 
All but two patients were post-mastectomy patients with a sarcoma in the arm 
after a prolonged period of lymphedema. Two patients suffered from congenital 
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lymphedema in their leg and developed a sarcoma in this area. They were 
treated between April 1994 and October 2001 with melphalan and TNF via 
hyperthermic ILP. Patient characteristics, treatment, results and follow-up data 
are listed in Table 1. All patients are women, with an age range of 45 to 82 years 
(mean age 64.0 years), and a total of 16 ILPs is described. Previous radiotherapy 
had failed in 2 patients and chemotherapy in 1 patient, with either a short-lived 
response or no response at all. At time of referral to us all patients were 
considered to be candidates for amputation by their referring specialists. 
ILP 
The technique of the hyperthermic ILP with recombinant TNF and melphalan is 
described in detail elsewhere 16. Briefly, recombinant human TNF (Boehringer 
lngelheim GmbH, lngelheim/Rhein, Germany) and the cytostatic drug melphalan 
were obtained as sterile powder (1 00 mg) dissolved aseptically using solvent and 
diluents (Burroughs Welcome, London, UK). ILPs were performed under general 
anesthesia and normally took 3 to 5 hours. Isolation of the blood circuit of a limb 
was achieved by clamping the major artery and vein and by applying a tourniquet 
to compress the remaining collateral vessels. Perfusion was performed at the 
axillary, brachial, iliac, or femoral level. ILP consisted of a 90-minutes perfusion 
with 1 to 4 mg TNF, and a 10 mg/1 (leg) or 13 mg/1 (arm) volume of melphalan (25 
to 110 mg) at mild hyperthermia (39 to 40°C). In 2 patients 0.2 mg Interferon was 
used according to the protocol that was in effect at the moment of perfusion. 
Composition of the perfusate was as follows: the priming volume of 700 to 850 ml 
consisted of 400 to 500 ml blood (50% RBCs, 50% plasma), 200 to 400 ml 5% 
dextran 40 in glucose 5% (lsodex; Pharmacia, Uppsala, Sweden), 10 to 30 ml 
8.4% sodium bicarbonate, and 0.5 ml of 2500 to 5000 IU heparin. TNF was 
injected as bolus into the arterial line, provided limb tissue temperature was 
above 38°C. Melphalan was administered 30 minutes later, at limb temperatures 
between 39 and 40°C. At the end of the ILP, the limb was washed with at least 2 I 
of 6% dextran 70 (Macrodex; Pharmacia, Uppsala, Sweden). 
Response evaluation 
CR was defined as the disappearance of all measurable disease in the limb for 
longer than 4 weeks, PR as regression of the tumor size by greater than 50% for 
46 
Isolated perfusion in Stewart Treves patients 
more than 4 weeks, no change (NC) as regression of less than 50% or 
progression of less than 25% for longer than 4 weeks, and progressive disease 
(PD) as greater than 25% disease progression. Responses were standardized 
according to World Health Organization criteria. 
Assessment of toxicity 
Regional toxicity was graded according to Wieberdink et a/.21 as follows: 1 = no 
toxicity, 2 = redness and slight edema, 3 = considerable edema or erythema with 
some blistering, 4 = extensive epidermolysis or obvious damage to the deep 
tissues, causing definite functional disturbances, or threatening, or manifest 
compartmental syndrome, 5 = reaction requiring amputation. Systemic toxicity 
was graded according to Eastern Cooperative Oncology Group (ECOG)-WHO 
criteria. 
RESULTS 
Treatment outcome 
Results are shown in Table 1. Sixteen ILPs with TNF plus melphalan were 
performed in 1 0 patients. All patients would have been candidates for 
exarticulation of the extremity. After ILP we observed an 87% overall response 
rate (CR+PR), 1 pattent had a mixed response and 1 patient failed to respond to 
the therapy. In 9 perfusions (56%) a complete response was achieved and 5 
perfusions (31%) resulted in a partial response. Limb salvage was achieved in 8 
patients (80%) with a mean follow-up duration of 34.8 (3-115+) months. 4 
patients received a second or even third ILP upon recurrent disease after a 
period of CR or PR achieved by the previous ILP. Figure 1 AJB/C shows clinical 
pictures of patient number 2 who is still alive with no evidence of disease 115 
months since her perfusion. 
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Patient Sex/Age No. of Site Size P/R Grade Stage Type Final Duration Limb Dead or Cause of Follow· ;:). 
No. (years) tumors (em) ILP outcome response Salvage Alive death up in = 
(months) months 0 1 1'{ F /78 >100 Lo Arm 1x1 R 2 2 Brach CR 20 ::r 
2"" F /80 >100 LoArm 3x2 R 1 2 Axil CR 13 ru "0 
3'' F /82 >100 Lo Arm 1x1 R 1 2 Axil PR 2 Yes 0 CVA 47 ~ 
2 F /67 >100 Total arm 1x2 p 1 1 Axil CR >115 Yes A, NED 115+ 0.l 
3 1'1 F /45 >100 Up Leg max 5x5 p 2 1 Iliac PR 3 
2"" F /47 >100 Up Leg max 5x5 R 2 2 Iliac PR 4 No A, NED 82+ 
4 F /52 >30 Up Arm 3x4 p 1 1 Axil PR 2 Yes 0 PO, lung 3 
mets 
5 1'1 F /67 >20 Lo Arm/ hand 8x4 p 1 1 Axil CR 18 
2"" F /69 >20 Up Arm 2x3 R 2 2 Axil CR >12 Yes A, NED 34+ 
6 F /60 >50 Up Arm/ elbow 7x14 p 1 1 Axil NC NC No A, NED 15+ 
7 F /65 4 Up+ Lo Arm 6x4 R 1 2 Axil MR 3 Yes 0 PO, lung 8 
mets 
8 1" F /77 >30 Lo Arm max5x4 R 2 2 Brach CR 19 
2"" F /78 >20 Up+ Lo Arm max3x3 R 1 2 Axil CR 13 Yes A, NED 46+ 
3'' F /80 >20 Up+ Lo Arm max8x4 R 1 2 Axil CR >11 
9 F /78 >20 Up Arm 1 X 1 p 1 1 Axil CR >6 Yes A, NED 6+ 
10 F /46 >20 Lo Leg 8x4 p 1 1 Fern PR >5 Yes A 5+ 
Abbreviations : F = female ; M = male ; Lo Arm = lower arm ; Up arm = upper arm ; Up leg = upper leg ; Lo Leg = lower leg ; P/R = primary /recurrence ; Brach = brachial ; Axil 
= axillary ; Iliac = iliac ; Fern = Femoral ; CR = complete respone ; PR = partial response ; MR = Mixed Response consisting of 2x CR and 2x NC ; NC = no change. NED = no 
evidence of disease. 
Isolated perfusion in Stewart Treves patients 
Figure 1 Stewart Treves angiosarcoma in left arm; A pre-
perfusion overview, B pre-perfusion detail, C post-perfusion. 
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Limb salvage 
Limb salvage was achieved in 8 of 10 patients (80% ), see Table 1. One patient 
with an insufficient response (PR) showed evidence of extensive recurrent 
disease in her leg after her second perfusion. Another patient showed no 
response at all. They both underwent amputation of the perfused limb within 4 
months of perfusion. 
Systemic metastases and survival 
At a median follow-up of 34.8 (3-115) months only 2 patients have died of 
metastatic disease and one patient died of a cerebrovascular accident (Table 1 ). 
At this moment 1 patient is alive with local disease. The remaining 6 patients are 
alive without any evidence o.f local or systemic disease. 
Toxicity 
Regional edema (grade 3 according to Wieberdink) with some blistering and 
slightly disturbed mobility (Table 2) occurred after 4 perfusions. Grade 2 toxicity 
with redness and slight edema developed after 6 perfusions. In all other 
perfusions no signs of local toxicity were seen. 
Table 2 -leakage and Regional Toxicity 
·Patient mgTNF mg melphalan mg interferon Leakage% Wieberdink 
No. classification 
1 1s 3 36 0,2 <1 2 
2nd 3 33 0,2 <1 2 
3'd 3 45 0 2 3 
2 3 42 0,2 <1 3 
3 1st 4 100 0 6 1 
2nd 4 110 0 <1 1 
4 3 50 0 0 3 
5 1st 3 40 0 10 2 
2nd 2 32.5 0 0 2 
6 2 40 0 0 1 
7 3 25 0 0 2 
8 1st 3 32.5 0 1,5 3 
2nd 1 33 0 0 2 
3'd 3 33 0 0 1 
9 1 40 0 0 1 
10 4 45 0 0 1 
Transient motor neurapraxia of less than 6 months was seen after 2 perfusions. 
Overall no severe regional toxicity was observed in spite of lymphedema being 
. present in all extremities prior to the (first) ILP. 
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Systemic toxicity was absent to mild and easily manageable. There have been no 
cases of toxic shock, liver toxicity, haematotoxicity or renal dysfunction. In 3 
perfusions a transient period of fever between 39 and 40°C followed ILP as at the 
time of the program no NSAIDs were administered immediately after the ILP. 
Total days of admission varied between 4 and 14 with a mean of 8.1 days. 
DiSCUSSION 
In this unique patient population of 10 patients with this rare, limb threatening 
vascular sarcoma we demonstrate that amputation can be avoided in the majority 
of patients by treating the condition with an ILP with TNF plus melphalan. Also 
survival has been remarkably high compared to the other reports in the literature. 
7 patients are still alive, 6 with no evidence of disease, at a mean follow up of 35 
months and a maximum follow-up of almost 10 years in a patient with over 100 
tumors before treatment. In literature there is no comparable patient group 
treated in this fashion. Various treatment regiments have been tried; radiation 
therapy, amputation or disarticulation, intravenous chemotherapy or combinations 
of these modalities 12. While there have been anecdotal reports of long-term 
survivors following systemic chemotherapl2·23 , overall there has been limited 
success at treating Stewart Treves with chemotherapy. The 5-years survival was 
as low as 13.6% in a report by Sordillo et a/11 . He reviewed 44 cases seen at the 
Memorial Hospital, New York City. He reported a median survival of 48 months in 
11 patients treated with amputation compared to a 20 months median survival in 
those patients treated with radiation therapy or chemotherapy. They conclude 
that surgical treatment should consist of either wide excision or amputation. A 5-
year survival of only 8.5% was reported by Woodward et at24. Yap eta/. reviewed 
22 patients seen at M.D. Anderson Hospital for post-mastectomy 
lymphangiosarcoma over a 20-year period. 13 patients were treated regionally, 
systemically, or both, with a variety of single or combination chemotherapeutic 
agents; the overall response rate was 42%23. 5 patients who failed to respond to 
chemotherapy had a median survival of 4 months, whereas the 6 chemotherapy 
responders had a median survival of 26.5 months. 2 cases described by 
Kaufmann et a/. comprehend long-term survivals after combined modality 
treatment with Actinomycin-D chemotherapy and high dose radiation therapl5 . 
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They survived at least 13 and 19 years respectively; nonetheless in the first case 
an amputation of the arm was performed. Overall, even in the setting of initial 
surgical treatment, survival was poor ( <40%) in a collective comparison of 160 
cases reported in literature 12. 
Length of survival in untreated patients is only 5-8 months24. Planning of 
appropriate therapy for these patients is dependent on the presence or absence 
of metastatic disease at the time of presentation. Death from Stewart Treves 
Syndrome usually occurs as a result of pulmonary metastasis, while spread of 
disease to bone and liver may also occur. 
The rationale of the combination of TNF and melphalan delivered locally is to 
make use of targeting both the stromal neovascular compartment and the cancer 
cell compartment of the tumo~6-28 . The permeability enhancing effect of TNF has 
also been demonstrated in a rat ILP model to significantly increase intra-tumor 
melphalan concentrations as a key explanation for the synergistic antitumor 
effects observed29 . The resulting effect is a rapid and profound necrosis. The 
selective destructive effects of TNF-ILP on tumor-associated vessels have been 
illustrated in previous publications by means of pre and post perfusion 
angiographies 17. In sarcoma patients we have clearly shown with magnetic 
resonance spectrometry studies that the metabolic shut down of tumor is virtually 
complete within 16 hours after the perfusion, confirming the likelihood of TNF 
mediating its most important effect on the tumor vasculature30. Our results 
demonstrate that a combined treatment with melphalan and TNF can lead to 
good clinical response rates in patients with extensive disease who were 
candidates for amputation. This implies that with the ILP we have a new 
treatment option in the management of Stewart Tre'(es angiosarcoma. 
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ABSTRACT 
Background: Recurrent soft tissue sarcoma (STS) in a previously operated and 
irradiated area can usually only be managed by amputation. Tumor Necrosis 
Factor (TNF) based isolated limb perfusion (ILP) is an established alternative to 
achieve limb salvage but is assumed to required sufficient vasculature. Since 
radiotherapy is known to destruct vasculature, we wanted to evaluate 
retrospectively whether the outcome of ILP in patients previously treated with 
radiotherapy for their primary tumor nonetheless benefited from TNF treatment. 
Methods: A database of TNF-based ILPs at the Rotterdam Cancer Center was 
used. Out of 342 TNF-based ILPs done between 1991-2003, 30 ILPs were 
performed in 26 patients with recurrent STS in the irradiated field after prior 
surgery and radiotherapy. 11 patients (42%) had multiple tumors (2->20). All 
patients were candidates for amputation. 
Results: We observed 6 complete responses (20%), 15 partial responses (50%), 
no change in 8 patients (27%) and progressive disease in 1 patient (3%). Median 
duration of response was 16 months (3->56), at a median follow-up of 22 (3->67) 
months. The local recurrence rate was 45% in patients with multiple tumors and 
27% in patients with single tumors. 1 0 patients (35%) died of systemic 
metastases. Limb salvage was achieved in 17 patients (65%). Regional toxicity 
was limited and systemic toxicity minimal. 
Conclusions: TNF-based ILP can avoid amputations in the majority of patients 
with recurrent extremity STS in a prior operated and irradiated field. 
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INTRODUCTION 
The approval by the European Medicine Evaluation Agency (EMEA) of Tumor 
Necrosis Factor (TNF) in combination with melphalan in the setting of isolated 
limb perfusion (ILP) for the treatment of locally advanced soft tissue extremity 
sarcomas (STS), based on the excellent limb salvage results of multicenter trials 
in Europe, has added an important treatment modality to avoid amputations of 
the limb 14. Patients with local recurrences in the limb after prior surgery and high 
dose radiotherapy and patients with multiple sarcomas are usually all candidates 
for amputation of the extremity. 
In the early the TNF-based ILP program for irresectable extremity STS much 
attention was given to the post-ILP necrosis of the foot a particular patient treated 
by TNF-based ILP after prior resections, high dose radiotherapy and prior ILP 
with Cisplatin5 . It was speculated that the high dose radiotherapy might have 
resulted in damage to the vasculature of the foot. This might have rendered it 
susceptible to the toxic effects of the combination of high dose TNF and 
melphalan leading to complete necrosis of the "healthy tissues" in contrast to the 
usually selective toxic effects on the tumor vasculature only. This observation led 
to hesitation to offer a TNF-based ILP to patients with a local recurrence 
presented in a high dose irradiated area. In an attempt to avoid amputation we 
decided to offer a TNF-based ILP in all cases where amputation was the only 
option regardless of prior treatments. We performed 30 ILPs in 26 patients with 
tumor recurrences in irradiated limbs. Here we report on this unique experience. 
PATIENTS AND METHODS 
Between 1992 and 2003, 26 patients with recurrent STS initial treated with 
surgery and radiotherapy, were treated with an isolated limb perfusion (ILP) with 
melphalan and TNF. All patients were considered candidates for amputation at 
the time of referral because of extensive and/or irresectable disease. 
The technique of the ILP with recombinant TNF and melphalan is in detail 
described elsewhere2. Briefly, recombinant human TNF (Boehringer lngelheim 
GmbH, lngelheim/Rhein, Germany) and the cytostatic drug melphalan, obtained 
as a sterile powder (1 00 mg) were dissolved aseptically using solvent and 
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diluents (Burroughs Welcome, London, UK). ILPs were performed under general 
anesthesia and normally took 2.5 to 4 hours. Isolation of the blood circuit of a 
limb was achieved by clamping the major artery and vein and by applying a 
tourniquet to compress the remaining collateral vessels. Perfusion was performed 
at the axillary, brachial, iliac, femoral, or popliteal level. ILP consisted of a 90-
minutes perfusion with 1.5 to 3 mg (arm) or 2-4 mg (leg) TNF and a 10 mg/1 (leg) 
or 13 mg/1 (arm) volume of melphalan at mild hyperthermia. Maximum tissue 
temperatures were 39.5°C in the leg and 38.5°C in the arm. Composition of the 
perfusate was as follows: the priming volume of 700 to 850 ml consisted of 400 to 
500 ml blood (50% RBCs, 50% plasma), 200 to 400 ml 5% dextran 40 in glucose 
5% (lsodex; Pharmacia, Uppsala, Sweden), 10 to 30 ml 8.4% sodium 
bicarbonate, and 0.5 ml of 2500 to 5000 IU heparin. TNF was injected as bolus 
into the arterial line, provided limb tissue temperature was higher than 38°C. 
Melphalan was administered 30 minutes later at limb temperatures between 38 
and 39SC. Directly after the ILP, the limb was washed with between 1 I (axillary) 
and 4 I (iliac perfusion) of physiologic saline solution and 6% dextran 70 
(Macrodex; Pharmacia, Uppsala, Sweden). 
EVALUATION OF RESPONSE AND TOXICITY 
An assessment of the tumor response was performed at least twice between four 
and twelve weeks after perfusion. Complete response (CR) was defined as the 
disappearance of all measurable disease in the limb for more than 4 weeks, a 
partial response (PR) as tumor size regression by greater than 50% for more 
than 4 weeks, no change (NC) as regression of less than 50% or progression of 
less than 25% for longer than 4 weeks, and progressive disease (PO) as more 
than 25% disease progression. In those patients where a resection of residual 
tumor and/or necrotic tissue mass was performed after ILP, a histological 
response rate was assessed by determining the percentage of necrosis. Clinical 
responses were standardized according to World Health Organization (WHO) 
criteria. 
Regional toxicity was graded according to Wieberdink et a/.6 In this Grade 1 = no 
toxicity, Grade 2 = redness and slight oedema, Grade 3 = considerable oedema 
or erythema with some blistering, Grade 4 = extensive epidermolysis or obvious 
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damage to the deep tissues causing definite functional disturbances, or 
threatening or manifest compartmental syndrome and Grade 5 = reaction 
requiring amputation. Systemic toxicity was graded according to Eastern 
Cooperative Oncology Group (ECOG)-WHO criteria. 
RESULTS 
Over the past 1 0 years more than 340 patients with advanced melanoma or 
sarcoma were treated with an ILP using melphalan in combination with TNF in 
the department of surgical oncology at the Erasmus MC - Daniel den Hoed 
Cancer Center. 26 of these patients were previously treated with surgery and 
high dose radiotherapy (50-70 Gy) for their primary sarcoma and developed one 
or more irresectable local recurrences. One patient had known distant 
metastases at the time of treatment. Patient and perfusion characteristics are 
shown in Table 1. The group consisted of 15 men and 11 women, with a median 
age of 50 (range 21-84, mean 52) years. Median interval between treatment of 
primary tumor and recurrence of disease was 19 months and ranged between 0 
and 156 months. 
In all patients systemic toxicity after ILP was mild to moderate and easily 
manageable. More than 10% leakage was measured in five patients during 
perfusion, but this was without significant toxicity. When postoperative 
hypotension occurred it responded immediately to fluid administration and none 
of the patients required circulatory support with vasopressors. One patient 
experienced a fever over 40°C after the ILP, this however was reversible within 
24 hours. Mean Wieberdink toxicity was 2, and no patients required amputation 
due to perfusion damage. Mean stay in hospital after ILP was 9 days (range 3-
42). 
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Table 1: Characteristics of 26 recurrent sarcoma patients treated with ILP (N-30) after radiotherapy treatment. 
no of 1st- Duration 
Pt tu- 2nd p/r type Local Clinical Final of Limb Follow 
no sex age mars site histology grade rec interval ILP Toxicity outcome Histology outcome response salvage D/A -up 
(% (mont 
(months) (Wieberdink) necrosis) (months) hs) 
1 M 72 1 Up leg Fibro 2 R 19 Iliac 3 NC NC Yes DOD 17 
2 F 46 2 Wrist Synovia 1 RR 156 Brach 3 PR PR 2 No A, NED 59+ 
3 F 63 1 Lo leg MFH 3 RR 22 Pop 2 NC <50 (NC) NC No A, NED 49+ 
4 M 44 1 Loarm MFH 3 R 39 Brach 2 NC 10(NC) NC No A, NED 52+ 
5 M 74 1 Loarm MFH 3 R 33 Brach 2 CR CR 43 Yes ou 56 
6 F 27 2 Lo leg Kaposi 2 RR 14 Pop 2 PR PR 19 (+) Yes DOD 19 
7 M 48 1 Up leg MFH 3 R 156 Iliac 2 PR PR 9 Yes DOD 30 
8 F 81 4 Lo leg MFH 2 R 28 Pop 2 NC NC 9 22 
82 6 Lo leg+ MFH 3 RR 9 Fern 2 CR NA CR 2 No DOD 
Ankle 
9 M 72 3 Fos pop MFH 3 R 12 Iliac 2 PR PR 9 Yes DOD 22 
10 F 50 1 Loarm MFH 2 R 38 Brach 3 NC NC 67+ 
50 1 Loarm MFH 2 R Brach 2 PR >50 (PR) PR 5 No A, NED 
11 F 33 6 Up leg Leio 3 RR 9 Iliac 2 PR 100 (CR) CR 8 44 
34 2 Up leg Leio 3 RR 6 Iliac 2 PR NA PR 17 Yes DOD 
12 M 22 1 Up arm Schwan 1 R 24 Axil 1 NC <10 (NC) NC Yes DOD 20 
13 F 84 3 Lo leg MFH 3 R 19 Pop 2 PR >50 (PR) PR 9 No DU 26 
14 M 41 1 Lo leg Synovia 2 RR 24 Fern 1 PR >50 (PR) PR 57+ Yes A, NED 57+ 
15 M 72 1 Up leg Schwan 2 R 26 Iliac 1 CR CR 44+ 44+ 
75 1 Up leg Schwan 3 RR 30 Iliac 1 PR PR 10+ Yes A, NED 10+ 1ii 
16 M 25 1 Fos cub Lipo 3 R 14 Brach 1 PR 100(CR) CR 12+ Yes AWD 12+ 0 ru 17 F 21 10 Up+ Lo Agfibro 1 RR 9 Iliac 3 PR PR 30+ Yes A, NED 30+ <D 
leg 0. 
18 M 72 3 Up leg+ MFH 2 RR 0 Fern 1 PR PR 21+ Yes A, NED 21+ "0 
Fos pop <1> 2' 19 M 33 3 Up leg+ Desma 1 RR 12 Iliac 2 PR PR 16+ Yes A, NED 16+ (/) 
Fos pop a· 
20 F 33 1 Fos pop Desma 1 RR 14 Fern 2 NC NA NC 15+ Yes A, NED 15+ :J 
Up+ Lo :;· 
21 M 20 8 leg Agfibro 1 RR 0 Iliac 3 PR PR 9+ Yes A, NED 9+ (/) 
22 M 40 1 Fos cub Synovia 3 R 32 Brach 2 NC <50 (NC) NC No DOD 22 <D 
23 F 54 3 Up leg+ Neuro 2 R 98 Iliac 1 CR 100 CR 22+ Yes A, NED 22+ :!! ru 
Fos pop ;::l. 
24 F 53 1 Up arm MFH 3 RR 6 Axil 2 PO PO No A 3+ -1 
25 M 72 1 Loarm Fibro 3 RR 93 Brach 1 PR PR 26+ Yes A, NED 26+ ro < 26 M 79 1 Loarm Pleio 3 RR 2 Brach 1 NC >50 (PR) PR 3 No A, NED 14+ <1> (/) 
"0 
Abbreviations : F = female ; M = male ; Histology : explained in tekst ; La Arm = lower arm ; Up arm = upper arm ; Up leg = upper leg ; P/R = primary /recurrence ; R = II (j) recurrence ; RR = re-recurrence; Brach = brachial ; Axil = axillary ; Iliac = iliacal ; Fern = femoral ; Pop = poplitial ; CR = complete respone ; PR = partial response ; NC = no ..... change; PD = progressive disease ; NA = not available ; NED = no evidence of disease; DOD = died of disease ; DU = death unrelated to disease ; AWD = alive with disease 
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A major tumor response was seen in 21 of 30 perfusions (70%), with a partial 
response in 15 patients (50%) and a complete response in 6 patients (20%). 9 
perfusions (30%) were not followed by any significant tumor response; 4 of these 
patients (n° 3,4,22,24) underwent an amputation of the limb. Two patients died of 
systemic disease with tumor present in their limb (n° 1, 12). Patient n° 8 had a 
mixed response to the first perfusion, with 4 out of 6 tumors showing a CR but 2 
tumors not responding at all, resulting in a NC score. The two remaining tumors 
responded well to the repeated perfusion scheduled 13 months after the first ILP. 
However, she relapsed within 3 months after the second perfusion and eventually 
underwent an amputation. Patient n° 1 0 responded insufficiently to the first 
perfusion but showed a partial response after a second ILP 7 months later. Due 
to a local recurrence, an amputation had to be performed after 1 0 months. In 
patient n° 20, the clinical response was insufficient for a PR score. However, the 
tumor had shrunk enough to allow for a resection. Histological responses could 
be established in 11 patients who were treated with an additional tumor resection, 
which in 3 patients showed much more necrosis in the tumor remnant than 
clinically expected (patient n° 11, 16,26). 
In 17 out of 26 (65%) patients limb salvage could be achieved. Duration of 
response was defined as the time from ILP until first evidence of local recurrent 
disease, and varied from 2 to 57 (and ongoing) months with a median of 12 
months (mean 17). Median follow-up of patients was 22 months (range 3 to >61 
months, mean 29). 
In 9 patients (11 perfusions) the tumor recurred locally after ILP, in 4 patients (4 
ILPs) with a single tumor (24%) and in 5 patients (7 ILPs) with multiple tumors 
(54%). An amputation had to be performed to achieve local control in 5 of the 
patients, while in 3 patients no amputation was performed because of the poor 
short-term prognosis due to systemic metastases. In one patient (n° 5) a local 
recurrence occurred 43 months after the perfusion, which could primarily be 
resected. This patient died one year later due to lung carcinoma. Nine patients 
developed systemic metastases after ILP. There was no significant difference in 
response between low-grade or high-grade tumors. There was no correlation 
between tumor size and subsequent tumor response. 
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DISCUSSION 
Our experience with 30 TNF-based ILPs in 26 patients with irresectable extremity 
STS recurrences in limbs previously treated with surgery in combination with high 
dose radiotherapy shows that even in this patient population limb salvage can be 
achieved in a majority of patients. Moreover, limb salvage was achieved in 65% 
of the patients in spite of multiple recurrences being present in 42% of the 
patients. Furthermore, we have shown that TNF-based ILP in previously highly 
irradiated limbs is not associated with an increased local toxicity or complication 
rate. 
In general, the management of extremity sarcomas has moved away from 
ablative surgical procedures towards function preserving surgery and is often 
combined with radiotherapy. As a result an increasing proportion of patients now 
incur locally recurrent sarcoma arising in previously irradiated areas. Amputation 
might be the most effective treatment option in this selected group of patients 
with local recurrences, but although this will improve local disease control it does 
not affect overall survival rates7-11 . Since amputation implies a significant 
decrease in quality of life, treatment modalities that guarantee preservation of the 
extremity as well as good limb function have become more important. Surgical 
resection of recurrent tumor in a previously irradiated field is often impossible as 
it usually requires the resection of all tissue exposed to a high radiation dose of 
60-70 Gy. This can occasionally be dealt with by free transfer of vascularised 
tissue, but in most cases will require an amputation. 
To compare our experience with data from the literature is not easy since 
comparable series of patients with recurrent soft tissue sarcomas in an irradiated 
field are not at hand. Moreover, 42% of patients in our series had multiple tumors, 
and these cases are usually not present in series that discuss the application of 
single use or combinations of re-surgery and/or re-irradiation of the recurrent 
sarcoma. Thus, comparison to data from the literature is limited to cases with 
single tumor recurrences after prior surgery in combination with radiotherapy. 
The results after re-irradiation are reported by Essner et a/. in a group of 32 
patients who received a second course of radiation for soft tissue sarcoma 12. In 
this group 84% of patients showed benefit from pre-operative radiotherapy in 
combination with subsequent surgery. Local excision of recurrent tumors followed 
63 
Part II - Chapter 4 
by a second course of post-operative radiation resulted in a local failure in 8 of 14 
patients (57%) and could not be recommended as a valuable therapy. 
The use of external beam therapy is restricted to patients with large tumors lying 
at least partially outside the previous treatment volume. When soft tissue 
sarcomas recur in a previously irradiated area, further external beam radiation is 
often not possible. Here brachytherapy allows a radiotherapeutic alternative in an 
attempt to reduce the risk of further local recurrence 13. Pearlstone eta/. reported 
on 26 patients who underwent resection and peri-operative brachytherapy in 
conjunction for recurrent STS14. At a median follow-up of 16 months, they 
reported a 5-year local recurrence-free survival rate of 52%, and a 33% disease-
free survival. This experience shows that in a series with single tumor 
recurrences the local control rate is still far from optimal. In addition, 15% of all 
patients experienced major wound complications that warranted re-operations. 
Another study by Nori et a/. describes 40 patients treated with brachytherapy, 
with a 5-year local control rate of 68% and a 12.5% severe wound complication 
rate 15. Catton eta/. advocate combined conservative surgery with re-irradiation to 
be the primary salvage therapy for patients who fail combined therapy and who 
are suitable for conservative re-excision 16. In this highly ·selective patient 
population local control for patients treated with conservative excision without 
radiation was only 36%, compared to 100% for conservative surgery with re-
irradiation. A very high proportion of patients (60%) experienced post-radiation 
complications. Obviously this patient population, eligible for conservative surgery 
does not even resemble the patient population with single tumor recurrences that 
we have treated with TNF-based ILP, let alone the patients with multiple tumors. 
Up to now trials with systemic neoadjuvant chemotherapy have failed to achieve 
any significant improvement in the survival of patients with primary or recurrent 
STS17• According to our findings there are no data available in the literature that 
describe the use of chemotherapy alone or in combination with the above 
mentioned therapies for recurrent sarcoma in previously irradiated areas. 
Regarding locoregional toxicity, no enhanced toxicity was observed compared to 
TNF-based ILP in patients without prior surgery in combination with radiotherapy. 
In essence TNF-based ILP has no increased regional toxicity over ILP with 
melphalan alone18 . Regarding systemic toxicity, no toxicity of importance was 
observed in this patient population. This was the case in patients without 
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significant leakage as well in the few patients with significant leakage during the 
perfusion and is in line with earlier reports on our experience with these patients 
19
•
20
. This underscores our opinion that TNF-based ILP is a safe procedure and 
should be considered in all patients with limb threatening tumors, irrespective of 
age, number of tumors or prior therapies4•21-23. 
In conclusion, we want to state that our experience clearly demonstrates that 
extremities should not be amputated without considering a TNF-based ILP for 
limb salvage. In the described patient population with extremely unfavorable 
characteristics of (multiple) limb threatening sarcoma recurrences in an irradiated 
field after prior surgery and radiotherapy, the achievement of a 65% limb salvage 
rate shows the efficacy of the TNF-based ILP approach to avoid amputations in 
what commonly are considered "lost cases" . 
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Tumor vascularity correlates with response after IHP 
ABSTRACT 
Introduction: Isolated hepatic perfusion (IHP) with melphalan is currently 
performed both with and without Tumor Necrosis Factor (TNF) in clinical trials in 
patients with hepatic metastases. Previous studies led to the hypothesis that the 
use of TNF in isolated limb perfusion causes specific destruction of tumor 
endothelial cells and thereby induces an increased permeability of tumor 
vasculature. However, whether TNF contributes to the therapeutic efficacy in IHP 
remains unclear. 
Methods: We studied three different tumor types in an in vivo rat liver 
metastases model. These tumors, colon carcinoma CC531, ROS-1 
osteosarcoma and BN-175 soft-tissue sarcoma exhibit different degrees of 
vascularisation. IHP was performed with melphalan both with and without the 
addition of TNF. 
Results: IHP with melphalan alone resulted in a decreased growth rate in all 
tumor types. The addition of TNF resulted in a strong synergistic effect in the BN-
175 tumor. A complete response was achieved in the majority of the BN-175 
tumor-bearing rats. In vitro cytoxicity studies showed no sensitivity (CC531 and 
BN-175) or only minor sensitivity (ROS-1) to TNF, ruling out a direct interaction of 
TNF with tumor cells. The response rate in BN-175 tumor-bearing rats when TNF 
was co administrated with melphalan was strongly correlated with drug 
accumulation· in tumor tissue, as only in these rats a five-fold increase in 
melphalan concentration was observed. Secondly, immunohistochemical analysis 
of microvascular density (MVD) of the tumor showed a significantly higher MVD 
for BN-175 tumor compared to CC531 and ROS-1. 
Conclusions: These results indicate a direct relation between vascularity of the 
tumor and TNF-mediated effects. Therefore we conclude that the level of tumor 
vasculature of liver metastases forms an indication for the usability of TNF in this 
setting. 
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INTRODUCTION 
Tumor Necrosis Factor (TNF) is a cytokine with interesting potential in the 
treatment of cancer1. When administered systemically it is accompanied with 
severe toxicity. However when TNF is used loco regionally without systemic 
exposure and in combination with chemotherapy, it has very potent antitumor 
effects. Clinical trials of isolated limb perfusion (ILP) with recombinant human 
TNF and melphalan resulted in high complete response rates of 75-90% in 
patients with in-transit melanoma and unresectable sarcoma of the 
extremities2·3.4. This is in contrast to ILP with melphalan alone, which is relatively 
effective against small in-transit melanoma metastases5 , but achieves very poor 
results against large tumors such as soft-tissue sarcomas6•7•8. 
Several studies have been performed to elucidate the mechanism of TNF. In our 
preclinical ILP model, we observed drastic alterations in tumor microvasculature 
integritl. Others elegantly demonstrated that TNF in combination with IFN 
induced functional down regulation of av~3, resulting in detachment of the 
endothelial cells of the tumor vasculature10 . Moreover, angiographic studies 
performed in patients pre- and post-TNF perfusion show selective destruction of 
tumor-associated vasculature and histologic studies demonstrate haemorrhagic 
necrosis of the tumor11 . Recently we demonstrated what we consider a key 
explanation for the potent synergy between TNF and chemotherapy: an up to 6-
fold increase of intratumoral melphalan or doxorubicin concentration in rat 
sarcomas after ILP when high-dose TNF was co administrated12·13. These 
findings led to the hypothesis that TNF causes specific destruction of tumor 
endothelial cells and thereby induces an increased permeability of tumor 
vasculature. 
As a result of the favorable experience with the ILP system, other isolated 
perfusion settings have been developed14•15 . Especially the liver offers excellent 
opportunities for isolated perfusion. lrresectable liver metastases form a 
significant clinical challenge. Isolated hepatic perfusion (IHP) with melphalan with 
or without TNF is technically feasible and is currently performed in clinical trials in 
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patients with hepatic metastases 16•17•18. Whether TNF contributes to the 
therapeutic efficacy in IHP still remains unclear. 
Our findings in previous ILP studies led us to study whether TNF can improve 
tumor response in different tumors after IHP and, if so, to investigate the 
capability of TNF to augment drug accumulation in this perfusion setting. By 
addressing this question the usefulness of TNF in IHP might be clarified. Since 
the tumor-associated vasculature is the target of TNF, we expect that tumor 
microvessel density (MVD) is a predictor of the potentiating effect of TNF during 
isolated perfusions. Here we present data that indicate that the antitumor effect of 
TNF is correlated with the tumor microvessel density. 
MATERIALS AND METHODS 
Rat liver metastases model 
We used male inbred WAG/RIJ or Brown-Norway (BN) strain rats, weighing 250-
300 g, obtained from Harlan-CPS (Austerlitz, the Netherlands). The rats were fed 
a standard laboratory diet. All animals were housed under standard conditions of 
light and accommodation. The protocol was approved by the committee for 
animal research of the Erasmus University, Rotterdam, the Netherlands. The 
experimental protocols adhered to the rules outlined in the Dutch Animal 
Experimentation Act of 1977 and the published Guidelines of the UKCCCR for 
the Welfare of Animals in Experimental Neoplasia (UKCCCR, 1998). 
Three different tumors were used in this study. The weakly immunogenic colon 
carcinoma CC531 is a 1 ,2-dimethylhydrazine-induced, moderately differentiated 
adenocarcinoma transplantable in syngeneic WAG/RIJ rats. The estimated 
doubling time in vivo is about 6-8 days. The spontaneously originated non-
immunogenic osteosarcoma ROS-1 is also transplantable in the WAG-RIJ rat 
and in the liver metastases model it has a mean doubling time of about 4-5 days. 
The spontaneously originated non-immunogenic soft-tissue sarcoma BN-175 is 
the fastest growing tumor of the tumors tested, with an estimated doubling time in 
vivo of about 2-3 days and is transplantable in syngeneic BN rats. Following a 
standardized protocol, small viable tumor fragments of CC531, ROS-1 or BN-175 
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tumor fragments of 1 x2 mm2 were implanted under the liver capsule, one on the 
left and one on the right side of the left liver lobe, using a 19 G Luerlock needle. 
Experiments started at a fixed tumor diameter between 5 and 6 mm. When 
tumors reached a size of 20 mm in diameter or animals showed obvious signs of 
discomfort the animals were sacrificed. 
Drugs 
Recombinant human TNF (4.9-5.8x1 07 U/mg) was provided as a kind gift by 
Boehringer lngelheim GmbH, lngelheim/Rhein, Germany. Melphalan (L-pam, 
Alkeran, Well come Ltd, London, UK) was obtained as a sterile powder (1 00 mg) 
that was dissolved aseptically using solvent and diluent provided by Burroughs 
Wellcome (London, UK). 
Isolated hepatic perfusion 
A rat isolated liver perfusion model has been described in detail elsewhere 17. A 
high-level schematic representation is shown in Figure 1 . Anaesthesia was 
induced and maintained with ether (Merck, Darmstadt, Germany). During the 
surgical procedure, with an average duration of 60-75 min, rats were kept at a 
constant temperature using a warmed mattress. A mid-line laparotomy was 
performed and the hepatic ligament was exposed. The gastroduodenal side 
branch of the common hepatic artery was cannulated, positioning the tips of the 
cannula (0.025 outer diameter (OD), 0.012 in inner diameter (ID)) (Dow Corning, 
Ml, USA) in the proper hepatic artery. Through a small inguinal incision the 
femoral vein was exposed. To collect hepatic venous outflow a silicon cannula 
(0.047 OD, 0.025 in ID) (Dow Corning, Ml, USA) was introduced in the femoral 
vein and moved up into the caval vein positioning the tip of the cannula at the 
level of the hepatic veins. 
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Figure 1 Schematic representation of an IHP. 
Isolation of the hepatic vascular bed was obtained by temporarily ligating the 
common hepatic artery and the portal vein. The venous outflow limb was isolated 
by temporarily clamping the supra-hepatic caval vein and by applying a 
temporary ligature around the infra-hepatic caval vein containing the cannule, 
cranial to the right adrenal vein. The mesenteric artery was temporarily clamped 
in order to reduce splanchnic blood pressure. The circuit was primed with 1 0 ml 
Haemaccel (Behring Pharma, Amsterdam, the Netherlands). Arterial flow of 5 
ml/min was maintained with a low-flow roller pump (Watson Marlow type 505 U, 
Falmouth, UK). Rats were perfused for ten min with oxygenated Haemaccel in 
which melphalan and/or TNF was dissolved. This short perfusion time was used 
as we observed rapid clearance of melphalan from the perfusate in this time 
frame. Secondly, perfusion of the liver beyond 10 min may increase the risk of 
tissue damage to the liver, but also to the gut as blood flow to the gut is impaired 
during the perfusion. Afterwards a washout was performed by perfusing with 10 
ml of oxygenated Haemaccel. Heparin (50 IU) (Heparine Leo, the Netherlands) 
was added to the perfusate. The perfusate was oxygenated in a reservoir with a 
mixture of 0 2/C02 (95%:5%) and was kept at 38-39°C by means of a heat 
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exchanger and a warm water bath. A temperature probe was positioned in the 
lumen of the arterial catheter, 5 em from the catheter tip. 
Following the washout procedure, the clamps on caval vein, portal vein, hepatic 
artery and mesenteric artery were released. The gastroduodenal artery and 
femoral vein were ligated and the gastroduodenal and femoral cannulas were 
removed. 
In vivo antitumor efficacy study 
Treatment started at a fixed tumor size of 5-6 mm in diameter. Rats were 
perfused in random order. For this study we chose the melphalan dose which 
inflicted a partial tumor response during a pilot-dose finding study performed for 
each tumor type. So in the case of additive or synergistic effect of TNF on 
melphalan this could still be demonstrated in the growth curves of the tumors. All 
animals underwent IHP only once. CC531-bearing rats were treated with 50 J..lg 
melphalan (n=6), with 20 J..lg TNF (n=6) or with a combination of 50 J..lg melphalan 
and 20 J..lg TNF (n=6). ROS-1-bearing rats were perfused with 50 J..lg melphalan 
(n=6), with 20 J..lg TNF (n=B), or with a combination of 50 J..lg melphalan and 20 J..lg 
TNF (n=6). In the BN-175-bearing rats perfusions were carried out with 200 J..lg 
melphalan (n=6), with 20 J..lg TNF (n=6), or with a combination of 200 J..lg 
melphalan and 20 J..lg TNF (n=6). After IHP tumor size was measured via a small 
midline laparotomy every fourth day. Tumor volume was calculated by using the 
following formula: tumor volume=A2 x B x 0.4, where B is the largest diameter and 
A the diameter perpendicular to B, measured with a standardized calliper. In 
every treatment group, sham perfused rats (n=6) and untreated control rats (n=5) 
were included. 
In vitro cytotoxicity assay 
CC531 and BN-175 cells were grown in RPMI 1640 and ROS-1 cells in modified 
Eagle's medium (Gibco BRL, Paisley, UK) supplemented with 1 0% foetal calf 
serum (Harlan/Sera-Lab, UK), 1% penicillin (5000 IU/ml), 1% streptomycin (5000 
IU/ml) and 1% L-glutamine (200 mM) (all Gibco BRL) in a humidified incubator at 
3rc and 5% C02. Before usage, the cells were trypsinised (1 min, 3rC), 
centrifuged (5 min, 700 G), resuspended and the viability measured by trypan 
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blue exclusion. For in vitro testing of proliferation inhibition, 1.0x1 04 viable cells 
were seeded in flat-bottomed 96-well microtiter plates (Costar, USA). After 24 h 
the cells were incubated with different concentrations of TNF for 72 h ranging 
from 0 to 10 !Jg/ml. Afterwards cells were washed with PBS and fixed for 1 h with 
10% trichloroacetic acid at 4 oc. Growth of tumor cells was measured using the 
sulpharhodamine-B assay according to the method of Skehan et aP 9 • Tumor cell 
proliferation was measured using the formula: tumor growth = (test 
well/control)x1 00%. Five independent tests were performed for each point on the 
line. 
Measurement of melphalan in tissue 
After 5 min of the restoration of the circulation the perfused tumor and part of the 
liver were excised. The tissues were immediately frozen in liquid nitrogen to stop 
metabolism of melphalan and were stored at -80°C. Tumor and liver tissues were 
homogenised in 2 ml acetonitrile (Pro 200 homogenizer, Pro Scientific, CT, USA) 
and centrifuged at 2500 G. Melphalan was measured in the supernatant by gas 
chromatography-mass spectrometry (GC-MS). p-[Bis(2-chloroethyl)amino]-
phenylacetic acid methyl ester was used as an internal standard. Samples were 
extracted over tri-functional C18 silica columns. After elution with methanol and 
evaporation, the compounds were derivatised with trifluoroacetic anhydride and 
diazomethane in ether. The stable derivates were separated on a methyl phenyl 
siloxane GC capillary column and measured selectively by single-ion monitoring 
GC-MS in the positive El mode20 . 
Assessment of tumor micro vessel density by immunohistochemistry 
Cryosections of tumors were fixed for 15 min with 4% formaldehyde. After rinsing 
with PBS, sections were incubated for 1 h with 1:10 PBS diluted, mouse-anti-rat-
endothelial cell antibody (RECA-1, lnstruchemie, Hilversum, the Netherlands). 
For the negative control an aspecific mouse lgG was used (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Thereafter, sections were rinsed with PBS 
and incubated for 1 h with 1:100 diluted, in 5% normal rat serum in PBS, goat-
anti-mouse peroxidase-labeled antibody (DAKO, Carpinteria, CA, USA). After 
rinsing with PBS, positive cells were revealed by immunoperoxidase reaction with 
DAB solution (DAB-kit, DAKO) and counterstained with haematoxylin. For 
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microvessel quantification two independent persons performed a blinded 
analysis. Positive cells were counted in three different high-power fields 
(magnification x160) in each slide according to the method of Bosari et af-1. In 
total, three slides per tumor and three tumors per tumor type were evaluated. 
Statistical analysis 
In vitro bioassays and in vivo tumor response results were evaluated for 
statistical significance with the Mann-Whitney U-tests with SPSS8.0. The Mann-
Whitney U-test was used to compare melphalan concentrations in different 
groups and the Kruskai-Wallis test to compare the number of positive cells in 
different tumors. A significance level of P<0.05 was used in all analyses. 
RESULTS 
Tumor response after isolated hepatic perfusion 
The antitumor efficacy of IHP with melphalan both with and without TNF was 
evaluated for the CC531, ROS-1 and BN-175 tumor starting at an equal size of 5-
6 mm in diameter. In all groups, sham IHPs with perfusion medium only were 
performed. The graphs in Figure 2 show the growth curves of CC531 tumor (A), 
ROS-1 (B) and BN-175 (C) after IHP with melphalan, with TNF, with both and 
after IHP in sham perfused rats. Perfusion with melphalan alone significantly 
reduced tumor growth rates compared with sham perfused animals in all tumor 
types. When IHP was performed in BN-175-bearing rats with the combination of 
melphalan and TNF, a dramatically enhanced tumor response was observed in 
all animals. This is a significant reduction of mean tumor volume compared with 
rats perfused with either TNF only or melphalan alone (P<0.005 and <0.01, 
respectively). In the CC531 or ROS-1 tumors no synergy between TNF and 
melphalan was observed. 
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Figure 2 Growth curves of in vivo tumors after IHP. Each group contained at least 6 
animals. Mean values (±s.e.m.) are shown; (A) CC531, (B) ROS-1, (C) BN-175. 
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In vitro cytotoxicity assay 
The effect of TNF on the growth of tumor cells in vitro was determined to evaluate 
whether the synergistic effect of TNF could be related to direct tumor cell toxicity. 
The calculated concentration of TNF in the perfusate during IHP in vivo is 
approximately 1.5 !Jg/ml. In vitro tumor cells were exposed to a range of TNF 
concentrations varying from 0 to 10 !Jg/ml. The growth curves are shown in 
Figure 3. It is demonstrated that the BN-175 and the CC531 tumor cell line did 
not show significant sensitivity to TNF. Only the ROS-1 tumor cells were 
moderately sensitive to TNF, as a growth inhibition of up to 30% at 10 !Jg/ml was 
observed. 
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Figure 3 In vitro growth curves of tumor cells upon exposure to TNF; CC531 (e), ROS-1 (+), BN-
175 (1111). Six independent assays were performed in duplicate for eacr point on the line. Mean 
values (±s.e.m.)are shown. 
Melphalan concentration in tumor and liver tissue 
In this perfusion setting, in which the dose of TNF is 20% of the dose used in ILP, 
an enhanced drug accumulation in tumor tissue might take place as well, as 
observed after TNF based ILP. In order to investigate this mechanism,_ melphalan 
concentrations were measured in tumor and liver tissues after IHP with 
melphalan both with and without TNF. In the. CC531 and ROS-1, tumors, 
melphalan concentration did not increase significantly after IHP with melphalan 
and TNF (Figure 4A,B). After IHP with melphalan alone in the BN175 tumor-
bearing rats the melphalan concentration in tumor and liver tissue were identical 
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(Figure 4C). After IHP with TNF however a more than 5-fold increase of 
melphCllan in tumor tissue is measured compared to tumor tissue after IHP 
without TNF; (P<0.05). This demonstrates that an augmented drug accumulation 
can also be achieved in the IHP setting when TNF is co administered. 
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Figure 4 Melphalan concentrations in liver and tumor tissue 
after IHP with melphalan with or without TNF. Six IHPs were 
performed per tumor type. Mean values (±s.d.) are shown. 
(*=P<0.05 vs tumor melphalan concentration after IHP with 
melphalan alone); (A) CC531, (B) ROS-1, (C) BN-175. 
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Assessment of tumor micro vessel density 
We already hypothesized that TNF enhances intratumoral concentrations of 
chemotherapeutics by increasing leakage of tumor vessels. The increased 
· uptake of melphalan might therefore be correlated with the microvessel density 
(MVD) of the tumor. Quantification of the MVD was performed by 
immunohistochemical staining of endothelial cells. The microvessel count of the 
colon carcinoma CC531 and the osteosarcoma ROS-1 were equal (Figure 5). 
The soft-tissue sarcoma BN-175 however showed a significantly higher MVD 
than CC531 and ROS-1. These results indicate a relation between vascularity of 
the tumor and TNF-mediated effects. 
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Figure 5 Microvessel count of CC531, ROS-1 and BN-175 tumors. Mean 
values (±s.e.m.) are shown (*=P<0.001 vs CC531 and vs ROS-1 ). 
DISCUSSION 
In the present study, we demonstrated that addition of TNF to IHP with melphalan 
results in strongly improved response rates in a tumor with high vascular density. 
In vitro, no or only minor sensitivity of tumor cells to TNF was. found. Even in 
ROS-1 tumors, which are moderately sensitive to TNF in vitro, IHP with TNF 
alone showed no tumor response. These results strongly indicate that in vivo 
indirect mechanisms mediated by TNF in combination with melphalan determine 
antitumor effects in IHP. Our results support the notion that this indirect 
mechanism is the selective destructive effect of TNF on the tumor-associated 
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vessels, thereby increasing vascular permeabilitl·10. To investigate this 
hypothesis, the melphalan uptake in liver and tumor tissue was measured after 
IHP both with and without TNF. Tumor melphalan concentrations were increased 
in all tumors but varied significantly in a tumor-type-dependent way. Moreover, 
enhanced uptake of melphalan by healthy liver was not observed. With TNF 
alone, at most some tumor growth was observed. Only the combination of TNF 
and melphalan resulted in a complete tumor response in the BN175 tumor. To 
elucidate this tumor-type-dependent response the MVD of the tumors was 
determined. We expected higher tumor vascularity in this tumor. Indeed a 
significantly higher MVD compared to the CC531 and ROS-1 tumors could be 
demonstrated. This indicates that TNF has specific tumor vascular mediating 
capacity in this perfusion model, which results in enhanced tumor responses in 
highly vascularised tumors. As a result of our findings in ILP and now also in IHP, 
we know that TNF is able to augment the accumulation of melphalan. The 
presence or lack of TNF-mediated synergy appeared to be independent of tumor 
size as also in smaller (diameter 3-4 mm) or bigger (7-8 mm) tumors comparable 
tumor responses were observed (data not shown). We are of the opinion that this 
observation is essential in understanding and explaining the impressive 
responses seen in the experiments. 
Changes in vascular permeability in patients who underwent IHP with TNF was 
studied by Alexander et a/16. Vascular permeability was measured by diffusion of 
radio-labeled 131 1 albumin in liver and tumor tissue. A significant increase of the 
131 1 albumin post-perfusion could be demonstrated compared to 131 1 albumin 
levels measured before perfusion. However, this rise was equal in tumors 
perfused with or without TNF. A TNF independent mechanism of the increased 
endothelial permeability was suggested by the authors. However, in the present 
study, we demonstrate that TNF is effective in increasing vascular permeability 
for melphalan selectively in tumor tissue. A more important finding is that this 
effect could only be found in the highly vascularised BN-175 tumor. The results of 
Alexander eta/, reported on intratumoral 131 1 albumin concentrations were mainly 
based on colorectal carcinoma liver metastases. In hypovascular rat colon 
carcinoma, we could also not find an increase of intratumoral melphalan. We 
therefore hypothesize that the usual hypovascularity of colorectal metastases in 
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patients explains the lack of TNF-benefit in the experience as described by 
Alexander in patients, which correlates closely to our observations in our 
hypovascular colon cancer liver metastases model in rats. 
IHP with melphalan and TNF performed in patients with metastases of ocular 
melanoma or leiomyosarcoma showed overall response rates of 50-52%21 ·22 . 
Both tumor types are highly vascularized. A prolonged duration of response was 
found in melanoma patients: 14 months after IHP with TNF vs. 6 months after 
IHP without TNF (Alexander et al, 2000). After IHP with melphalan both with and 
without TNF in patients with colorectal liver metastases the mean duration of 
response was 8-10 months in both groups 16•23•24• The data we now present and 
the first reports of IHP in melanoma and sarcoma liver metastases strongly 
indicate that TNF has therapeutic potential in IHP in these patients. In patients 
with colorectal liver metastases however, IHP with melphalan alone may well be 
just as effective as combined with TNF. Therefore we conclude that the level of 
tumor vasculature of liver metastases forms an indication for the usability of TNF 
in this setting. 
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Improved TNF sensitivity after upregulation of EMAP II 
ABSTRACT 
Introduction: Tumor Necrosis Factor (TNF) is a proinflammatory cytokine with 
potent antitumor activity. Its clinical use in cancer treatment is limited by 
considerable toxicity after systemic administration and is currently confined to 
isolated limb and organ perfusion settings. A better understanding of the 
mechanisms of the TNF-induced antitumor effect may provide valuable insight 
into how its clinical use in cancer treatment could be expanded. The novel tumor-
derived cytokine, Endothelial Monocyte-Activating Polypeptide II (EMAP II) has 
been demonstrated to render a TNF-resistant tumor sensitive to TNF therapy. 
Methods: We demonstrate here that in vitro stable transfection of rat sarcoma 
cells leads to an upregulation of endogenous pro-EMAP II in these tumor cells. 
This gene transfer induced sensitivity to subsequent regional TNF treatment by 
means of an isolated limb perfusion (ILP) in rats. To confirm that this was indeed 
an EMAP II effect, tumor bearing rats were pre-treated with an intravenous 
injection of recombinant EMAP II followed by an ILP with TNF. 
Results: These experiments resulted in a comparable tumor response as was 
observed in the rats undergoing EMAP II gene therapy followed by TNF ILP. 
Conclusions: These results indicate that methods to introduce or upregulate 
EMAP II in tumors may lead to an increased applicability of TNF in clinical 
treatment strategies. 
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INTRODUCTION 
Studies of the antitumor activity of systemically administered TNF in humans 
have been hampered by severe toxicity at doses of the cytokine which are too 
low to cause a sufficient antitumor response 1. This situation changed when TNF 
was applied in the isolated limb perfusion (ILP) setting. The efficacy of the 
application of TNF in combination with cytostatic agents in ILP for the treatment 
of patients with in transit melanoma metastases or locally advanced soft tissue 
sarcomas has now been well established1·2·3. This treatment can be used as a 
limb-sparing neoadjuvant therapy when followed by local excision of residual 
tumor. TNF became a registered cancer drug in Europe based on results 
obtained in multicenter studies in which clinical response rates of 75% and limb 
salvage rates of 71% were observed in 196 patients previously classified as 
having unresectable tumors manageable only by amputation. Approval for the 
use of TNF in the setting of an isolated limb perfusion for locally advanced 
extremity grade 11-111 soft tissue sarcomas (STS) was given by the EMEA4. 
However in 25% of all patients an antitumor effect sufficient for limb preservation 
can not be ·achieved. The answer as to why this group of patients is not 
responding is not known. 
There is evidence that the mechanism of TNF does not act on tumor cells directly 
but acts indirectly by destruction of tumor associated endothelium5. This 
destruction may eventually lead to death of tumor cells when used in combination 
with an antitumor drug. The antitumor effects after TNF-containing ILPs can be 
extremely rapid, indicating that the TNF-mediated collapse of the tumor vascular 
bed may play an essential role in the antitumor mechanism. The selective 
destructive effects of a TNF ILP on tumor associated vessels have been illustrated 
in the clinic by means of pre- and post perfusion angiography1. Severe 
hemorrhagic necrosis accompanied with vascular destruction was observed after 
ILP with TNF in combination with melphalan. 
Our laboratory has developed isolated limb perfusion models with different 
tumors in rats to study prerequisites for improving efficacy and to study 
mechanisms of synergl·7 . These models closely mimic the clinical setting with 
respect to response rate and histopathology. The crucial observation has been 
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that TNF enhances the uptake of melphalan and doxorubicin in the tumors 
selectively and highly significantly 6. 
EMAP II is a tumor-derived cytokine with pro-inflammatory properties. It induces 
procoagulant activity on the surface of endothelial cells and 
monocytes/macrophages in vitro, as well as upregulation of E- and P-selectin 
expression and the ability to upregulate TNF receptor-1 expression on tumor 
vasculature. Furthermore EMAP II induces apoptosis and has antiangiogenic 
effects 1. These data led us to hypothesize that EMAP II could be of additional 
benefit in the TNF perfusion circuit. Wu et a/.8 defined a way to upregulate EMAP 
II production by means of retroviral transfection in a melanoma cell line. We used 
this method of transfection on a TNF-resistant soft tissue sarcoma. Here we 
describe the application of the sensitizing gene therapy and subsequent regional 
TNF treatment and its effects on in vivo tumor growth. Since EMAP II can have 
additional benefits in the long-term anticancer treatment through its 
antiangiogenic effect (e.g. by preventing neovasculature and outgrowth of 
metastases), and is toxic when injected systemically, a long lasting and local 
production of EMAP II in a tumor should be favorable. This can be maintained 
after retroviral transfection and subsequent upregulation of the protein synthesis 
by tumor cells. 
It is our goal to identify factors of TNF resistance or sensitivity and the potential 
role of EMAP II in this. 
MATERIALS AND METHODS 
Animals 
Inbred male Brown Norway rats, weighing 200 to 300 grams, were obtained from 
Harlan-CPB, Austerlitz, the Netherlands. All animals were kept at standard 
laboratory conditions and were fed a standard laboratory diet (Hope Farms, 
Woerden, the Netherlands). The experimental protocols adhered to the rules laid 
down in the "Dutch Animal Experimentation Act" (1977) and the published 
"Guidelines on the protection of Experimental Animals" by the council of the EC 
(1986). All animal studies were done in accordance to protocols approved by the 
Animal Care Committee of the Erasmus University of Rotterdam, the 
Netherlands. 
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Tumor eel/lines 
BN-175 is a non-immunogenic, rapidly growing soft tissue sarcoma syngeneic in 
Brown Norway rats, with a tumor doubling time of approximately 2 to 3 days. This 
tumor was implanted into the flank of donor rats and passaged serially. For this 
study we used small tumor fragments (± 1 mm2) that were implanted 
subcutaneously into the right hind limb just above the ankle. All surgical 
interventions were performed at a tumor diameter between 5 and 1 0 mm, at least 
7 days after implantation. Rats were sacrificed when tumor diameter exceeded 
25mm. 
The HUVECs used were obtained from BioWhittaker Europe and consisted of 
pooled cells by multiple donors. 
Drugs 
Recombinant human Tumor Necrosis Factor-a (hTNF; 4.9-5.8 x 107 units/mg), 
recombinant human EMAP II (hEMAP II; 3,85 )lg/ml) and antibodies directed to 
hEMAP II were provided as a kind gift by Dr. G. Adolf (Boehringer lngelheim 
GmbH, Vienna, Germany). 
Transfection of BN-175 tumor cells with the EMAP II gene 
Viral supernatant from the Gibbon Ape ecotropic packaging cell line PG-WU was 
used to transfect the BN-175 tumor cell line. Tumors were grown in 6-well plates 
to approximately 40% confluence. The viral supernatant was then collected and 
filtered across a 0.45 micron low protein-binding membrane (Corning Costar, 
Cambridge, MA) and polybrene (Sequa Brene; Sigma) was added in a 
concentration of 1 ).11/ml supernatant. Tumor cells were washed twice with PBS 
and incubated for 6 hours on 3 subsequent days in an incubator at 37° C and 5% 
C02 . In between incubation with viral supernatant cells were given normal 
medium to recover. After 5 to 7 days the transfected tumor cells (named BN-E) 
were placed into 75 cm2 flasks and expanded under neomycin selection at 800 
)lg/ml. 
Detection of incorporation of hEMAP- in genomic DNA of rat tumor cells by PCR 
Transfected tumor cells growing in 800 )lg/ml neomycin were trypsinated and 
pelleted. DNA was extracted using the Qlamp DNA mini kit (Qiagen Inc.) and 
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amplified by PCR using primers specific for both a part of the EMAP II insert and 
the downstream retroviral IRES region. For EMAP the following primers were 
used: 5'-AATCGGATGGTGATTTTACTTTGTA-3' (EF-1) as the both times as the 
forward primer and backward: 5'-CATTTTATTTGATTCCACTGTTGC-3' (ER-1) 
with a PCR product of 333 bp for the EMAP part, and backward for IRES and 
EMAP: 5'-GAATGCTCGTCAAGAAGACAG-3' (ER-2), providing a 577 bp PCR 
product. PCR amplification was performed under the following conditions: 5 
minutes at 95°C, 35 cycles (94 oc for 45 seconds, 55°C for 45 seconds, 72°C for 
60 seconds), and 7 minutes at 72°C, soak at 4°C. Amplified PCR-products were 
subjected to gel electrophoresis on a 1% agarose gel containing ethidium 
bromide. 
Western blot analysis of transfected tumor cells for EMAP 
After transfection of the tumor cells, cells were harvested, washed and 
centrifuged. Cell pallets were lysed at 4oc in a buffer containing 50 mM TrisCI 
(pH 8.0); 150 mM NaCI; 0.02% Na-azide; 0.1% SDS; 1 11g/ml aprotinine; 5% Na-
deoxycholate; 1 % Nonidet P-40; DNAse I, 10 ng/ml and 100 11g/ml PMSF for 10 
min. Samples were vortexed and debris was pelleted by centrifugation at 15000 
G for 10 minutes. Supernatant protein content was determined by BCA protein 
assay (Pierce) and a final loading concentration of 120 (..Jg per sample was used. 
Lysates were mixed with Laemmli buffer containing 5% ~-mercaptoethanol, 
boiled for 5 minutes and electrophoresed on a 15% Acrylamide-gel using SDS-
PAGE. The membranes were subsequently blocked for non-specific binding 
overnight at 4 oc with PBS/ 5% nonfat dry milk/ 0.05% tween and incubated for 2 
hours with EMAP II polyclonal rabbit antiserum (diluted 1:2000 in PBS/ 5% nonfat 
dry milk! 0.05% tween). After washing thoroughly, the membranes were 
incubated for 1 hour with biotinylated goat-anti-rabbit lgG antiserum (diluted 
1:3000 in PBS/ 5% nonfat dry milk! 0.05% tween). Membranes were washed 
again and incubated with alkaline-phosphatase labeled streptavidine and 
developed with enhanced chemiluminescence by adding BCIP/NBT. 
Coagulation Assay 
Conditioned medium from wild-type BN-175 and BN-E tumor cell lines was tested 
for procoagulant activity using a two-stage coagulation assay. HUVECs were 
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sarcoma, it was shown that only when TNF was combined with melphalan or 
doxorubicin a tumor response could be reached. In comparison to the clinical 
setting, our rat model demonstrated partial or complete regression of the tumor in 
approximately 75% of rats receiving an ILP with melphalan plus TNF. We used 
the BN-175 soft tissue sarcoma to set up an experimental environment where we 
could improve the response rate to TNF. 
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Figure 2 Tissue Factor Assay. Lane 1 positive control, medium of 
cells treated with 1 ~g TNF-a; Lane 2 medium of untreated cells; 
Lane 3 wild-type tumor medium; Lane 4 transfected tumor medium. 
Briefly, small fragments (3-5 mm) of tumor were implanted subcutaneously into 
the right hind limb of the rat. About 7 to 8 days after implantation tumors reached 
an average diameter of 8-12 mm when treatment was started. Animals were 
anaesthetized with Hypnorm (Janssen Pharmaceutica, Tilburg, the Netherlands) 
and Ketamine (Apharmo BV, Arnhem, the Netherlands). Heparin (50 IU) was 
injected intravenously to prevent coagulation. To keep the rat's hind limb at a 
constant temperature, a warm water mattress was applied. Temperature was 
measured with a temperature probe on the skin covering the tumor and was 
maintained between 38 and 39 °C. The femoral artery and vein were cannulated 
with silastic tubing (0.012 inch 10, 0.025 inch 00; 0.025 inch 10, 0.047 inch OD 
respectively, Dow Corning, Michigan, USA). Collaterals were occluded by a groin 
tourniquet and time of isolation started when the tourniquet was tightened. An 
oxygenation reservoir and a roller pump were included into the circuit. The perfu-
sion solution consisted of 5 ml Haemaccel (Behring Pharma, Amsterdam, the 
Netherlands) in the sham perfusions, and TNF (50 11g) was added to the 
oxygenation reservoir as a bolus in the treatment group. A roller pump (Watson 
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Marlow, Falmouth, UK; type 505 U) recirculated the perfusate at a flow rate of 2.4 
ml/min. A washout with 5 ml oxygenated Haemaccel was performed at the end of 
the perfusion. After the perfusion, the cannulas were removed and the femoral 
vessels of the perfused limb were ligated. The extensive collateral circulation was 
capable to restore the blood supply of the perfused leg. 
Figure 3 Immunohistochemical staining with hEMAP II (100x). 
A) shows the non-transfected tumor. In B) we show a marked 
upregulation of the intracellular present hEMAP II 
The perfusion with the wild-type tumor took place 16 hours after intravenous 
injection with rEMAP II. In these experiments 50 11g recombinant EMAP II, 
dissolved in 200 111 PBS, was injected intravenously. Rats were closely monitored 
99 
Part Ill -Chapter 6 
Figure 4 Hematoxylin and eosin (HE) stained tumor sections (100 x). A) shows a normal 
morphology of wild-type (BN) viable tumor cells. In B) the transfected tumor is shown 
with an aspect of more profound necrosis, disruption of cell structure and smaller cells. 
afterwards and moderate but reversible toxicity was observed after IV 
administration. Subsequent tumor growth. was recorded daily by calliper 
measurement. Tumor volume was calculated as 0.4 x (A2 x B), where B 
represents the longest diameter and A the diameter perpendicular to B. 
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RESULTS 
Transfection of EMAP II gene 
Rat soft tissue sarcoma cells were transfected in vitro with retroviral particles 
containing the P-WU construct (BN-E) and appeared resistant to continuous 
exposure with 800 flg/ml neomycin, demonstrating effective transfection with the 
construct (data not shown). After 2 weeks of growing in selection media, genomic 
DNA was extracted from the transfected tumor cell lines. PCR analysis of 
expression of the EMAP II gene proved positive for the BN-E cell line (data not 
shown). Western Blot analysis of 120 !Jg protein of cell lysate of wild-type and 
transfected tumor cells, compared to 100 ng rEMAP II, demonstrated a band 
corresponding to the size of the human precursor EMAP II, approximately 34 kDa 
(Figure 1 ). We only show the results with normal growing tumor cells. In our 
ongoing experiments we would like to demonstrate the generation of active 
EMAP II (-22 kDa) that was used as a control in these experiments and 
intermediate cleavage products by inducing apoptosis in the tumor cells. 
However this expression seems to be very unstable, transient and shows 
tremendous variation. 
Coagulation Assay 
We wanted to test whether the EMAP II transfected cell line, BN-E, produced 
functional protein. We used a functional bioassay of EMAP II activity based on 
the induction of tissue factor expression on human endothelial cells. HUVECs 
were treated with conditioned medium of transfected tumor cells. As shown in 
Figure 2, a 6 hour exposure of HUVECs to medium conditioned by tumor 
transfected with EMAP II (BN-E) induced a 20 % increase in the production of 
tissue factor by these cells, as compared to treatment with conditioned medium 
from wild-type BN or medium alone. 
Immunohistochemical staining of hE MAP in rat tumor tissue 
The tumor model used for our in vivo studies was generated by subcutaneous 
injection of 2x1 06 transfected tumor cells in the hind limb of a syngeneic Brown 
Norway rat. Tumors were grown to an average diameter of 8-12 mm and we 
observed a growth rate corresponding to a wild-type tumor. As shown in Figure 3, 
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cells stained positive for EMAP II as compared to controls. On the H&E staining 
(Figure 4) the morphology of transfected tumor is altered with a tendency to more 
apoptotic cells. This however was not reflected in the growth rate of the BN-E. 
We regard this as apoptosis being induced by the increased EMAP II production 
of this tumor. 
Isolated limb perfusion in rats preceded by rEMAP II injection. 
50 J.Lg rEMAP II was injected intravenously in rats 16 hours prior to TNF 
perfusion. Rats showed a moderate toxic response immediately after injection 
nevertheless this was reversible within 4 hours. Figure 6 shows the tumor volume 
of animals treated with TNF perfusion after pre-treatment with rEMAP II. Sham 
perfusions after EMAP II injection were also performed. From the second day a 
significant difference in tumor volume was observed in TNF treated animals 
bearing the BN-E versus wild-type tumor. Tumors treated with sham perfusion or 
TNF-ILP alone continued to grow, the rEMAP II pre treated animals showed a 
delay in tumor growth after TNF-ILP. This difference was observed until the ninth 
day, when both groups started to develop the same growth rate. Both wild-type 
and BN-E tumor showed the same growth rate in the presence of systemically 
administered rEMAP II alone. 
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Figure 5 Growth curves of BN tumor after ILP with sham (111) n=5 and TNF ( +) n=7; BN-E tumor 
after ILP with sham (o) n=7 and TNF (~) n=5. 
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DISCUSSION 
The results presented in this study show that transfection with EMAP II of the 
TNF resistant tumor BN-175 will render this tumor TNF sensitive and responsive 
to ILP treatment with TNF. This approach could enhance efficacy in the clinical 
setting where 25% of patients with locally advanced limb threatening extremity 
soft tissue sarcoma do not respond to TNF + chemotherapy in the ILP setting for 
limb salvage to be achieved. 
8000 
"'-E 
.§_ 6000 
Cl) 
E 
::J 4000 0 
> 
... 
0 
E 2000 
::J 
-
2 4 6 8 10 12 14 
Days 
Figure 6 Results ILP in wild-type BN tumor. Control tumor (o) 
n=6, sham perfusion (T) n=5, TNF (0) n=7, EMAP II followed by 
sham perfusion (o), and ILP with EMAP II + TNF (•) n=6. 
By introducing the isolated perfusion as a mode to apply TNF in patients we have 
been able to achieve effective concentrations of TNF in the tumor region. 
Antitumor effects after TNF containing ILPs occur be extremely rapidly. This 
indicates that also in humans the TNF mediated collapse of the tumor vascular bed 
plays an essential role in the antitumor mechanism as previously demonstrated in 
clinical studies by pre and post perfusion angiographi 1. Moreover in studies with 
magnetic resonance spectrometry in sarcoma patients we have clearly shown that 
the metabolic shut down of the tumor is virtually complete within 16 hours after the 
perfusion, confirming the likelihood of TNF mediating its most important effects on 
the vasculature of the tumor11 . At the histopathological level these intravascular 
effects such as thrombocyte aggregation, erythrostasis, endothelial and vascular 
destruction have been described for the early stage changes after ILP which may 
resemble closely observations made in experimental tumor systems 11 . 
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Since TNF is known to act on the tumor endothelium a range of cytotoxic agents 
have been used in combination to cause an additional antitumor effect. After the 
initial destruction of tumor vessels these agents can exert their toxic effect on the 
tumor cells. 
Here we introduce an approach based on a different mechanism to improve the 
effect of TNF therapy. After the observation that varying tumors respond to TNF 
in a distinct manner, a cytokine that contributes to this variation was isolated. This 
cytokine, EMAP II, is produced by tumors and influences the formation of 
neovasculature in a number of ways, one of them being the upregulation of TNF-
R1 on tumor associated endothelial cells. This is an important finding in the 
context of the use of TNF in anticancer therapy. 
Therefore we investigated whether we could enhance the TNF-sensitivity of a 
non-responding rat sarcoma in vivo by transfecting the tumor with EMAP II, in 
order to increase its endogenous EMAP II content. EMAP II is a tumor-derived 
cytokine with pro-inflammatory properties, inducing procoagulant activity on the 
surface of endothelial cells and monocytes/macrophages in vitro as well as up-
regulating of E- and P-selectin expression and having the ability to upregulate 
TNF receptor-1 expression on tumor vasculature 12. The distribution of EMAP II 
protein is relatively restricted and usually associated with tissues that display high 
turnover and high levels of protein synthesis, e.g. tumor tissue 13. It was first 
isolated from the conditioned medium of the murine Meth-A fibrosarcoma (Meth. 
A). This tumor responds well to TNF therapy and investigators found that in the 
supernatant of this tumor the cytokine EMAP II was excreted. Studies have 
shown that EMAP II is capable of sensitizing resistant tumors to the antitumor 
effects of TNF14•15. In response to EMAP II exposure, endothelial cells are 
activated and the expression of TNF-R1 is upregulated, an effect which is known 
to take place between 16 and 24 hours after exposure to EMAP 11 15 . It led us to 
hypothesize that EMAP II could be of additional benefit in the TNF perfusion 
circuit. This enabled us to create a more sensitive tumor to TNF therapy, without 
the toxic side effects of systemic EMAP II application. In our next experiments we 
injected recombinant hEMAP in rats that were subjected to an isolated limb 
perfusion system with TNF 16 hours later. In a dose of 50 11g rEMAP per rat 
combined with 50 11g TNF we saw a significant decrease of growth of the tumors 
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with an immediate, although moderate and reversible, toxic reaction to the 
injected EMAP II. These results were comparable with the effect seen in the 
transfected tumor and suggest that this effect is mediated by EMAP II rather than 
an effect created by transfection of the tumor or an effect seen because of 
varying levels of EMAP II receptors. 
Isolated limb perfusion is an interesting method for new treatment modalities such 
as adenoviral-vector mediated gene therapy 16• 17. In our laboratory we have shown 
that ILP is the best and most selective method for effective homogeneous 
transvascular local gene-delivery by using adenoviral vectors. Experiments in our 
soft tissue sarcoma and osteosarcoma isolated limb perfusion models have clearly 
shown this by making use of luciferase-marker gene and LacZ gene 
methodologi8. Moreover we have shown that ILP with adenoviral-vector gene 
delivery of the cytokine IL-3 is the sole method in these tumor models to achieve 
adequate tumor responses, this in contrast other methods such as IV 
administration, intra-arterial administration or intratumor administration which fail to 
do so 17. It demonstrates that ILP is a valuable method to treat advanced limb 
tumors arid to develop new treatment modalities. 
The possibility of manipulating the sensitivity for TNF in a tumor in vivo also 
creates an opportunity for systemic application of TNF in future settings. If non-
invasive vectors can increase tumor sensitivity such that the TNF dose can be 
lowered we may be able to save patients the invasive perfusion procedure in the 
future, and may be able to administer TNF systemically in patients. 
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Gene transfer of IP-10 inhibits tumor growth 
ABSTRACT 
Background: Interferon-inducible protein 10 (IP-10) is an immunomodulatory 
chemokine recently recognized to have potent antiangiogenic activity in vivo. Due 
to difficulties in the stability, manufacture and chronic administration of 
recombinant forms of endogenous antiangiogenic proteins, antiangiogenic gene 
therapy has emerged as a promising new form of cancer treatment. 
Methods: We retrovirally transduced A375 human melanoma cells with the 
human IP-10 gene and injected cells subcutaneously into nude mice. IP-10-
transduced cells also were mixed with null-transduced cells in varying proportions 
before injection. 
Results: In vivo growth of IP-10-transduced melanoma cells was markedly 
diminished compared to parental or null-transduced cells, This growth inhibition 
was associated with a marked reduction in microvessel density. The degree of 
growth inhibition of tumors following injection of a mixed population of null- and 
IP-10-transduced cells was directly associated with. the fraction of IP-10-
transduced cells present. 
Conclusions: We conclude that retroviral transduction of human melanoma cells 
with the IP-1 0 gene leads to sufficient protein secretion to inhibit angiogenesis 
and tumor growth. These findings suggest that IP-1 0 gene therapy might be an 
effective therapy in patients with cancer. 
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INTRODUCTION 
Because tumors require angiogenesis for sustained growth 1 inhibition of tumor 
angiogenesis is an attractive new strategy for treating cancer patients. However, 
in vitro instability, manufacturing constraints and pharmacokinetic properties of 
recombinant forms of endogenous antiangiogenic proteins have led to preclinical 
investigations of gene therapy approaches to the antiangiogenic treatment of 
cancet'. Interferon-inducible protein 10 (IP-1 0) is a chemokine that, in addition to 
being a chemoattractant for stimulated T lymphocytes3, has been demonstrated 
to have antiangiogenic properties in vivo4. In our study, we evaluated the effects 
of retroviral IP-10 gene delivery and protein expression on human melanoma 
xenografts in nude mice. 
MATERIALS AND METHODS 
Cloning the human /P-10 gene 
Human umbilical vein endothelial cells (Cionetics, San Diego, CA) were plated 
overnight in EGM-2 medium (Cionetics). Cells then were stimulated with 
recombinant human interferon-gamma (1 00 IU/ml; R&D Systems, Minneapolis, 
MN) for 6 hr and total RNA was isolated using silica gel columns (RNeasy Mini 
Kit; Quiagen, Valencia, CA) according to the manufacturer's instructions. The 
RNA was treated with M-MLV reverse transcriptase (Life Technologies, 
Gaithersburg, MD) to obtain eDNA. The published sequence for human IP-10 
(GenBank accession number X02530)5 was used to derive PCR primers (sense, 
GATCAAGCTTCCACCATGAA TCAAACTGCGA TTCTGAT; antisense, 
GATCGGATCCTT ATT AAGGAGATCTTTT AGACATTTCCT), incorporating a 
Kozak consensus sequence6 upstream of the start codon. The IP-1 0 gene was 
cloned into the TA cloning vector (TOPO TA Cloning Kit; InVitrogen, Carlsbad, 
CA) and sequenced (ABI Prism 310 autosequencer; PE Applied Biosystems, 
Foster City, CA). 
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Figure 1 In vitro characteristics of IP-10-transduced tumor cells. (a) Human melanoma cells 
were transduced with retroviruses containing the null vector, pCLNCX, or the vector, pCLNC-
IP10, containing the human IP-10 gene. (b) Western blot demonstrated the presence of IP-10 
in cell supernatants from IP-10-transduced clones but not in cell supernatants from null-
transduced or wild-type (wt) cells. Clones 2 and 11 demonstrated the highest IP-10 expression 
of those tested. The lane labeled control contained recombinant human IP-10. (c) In vitro 
proliferation was measured by WST-1 colorimetric assay. Most clones, including clones 2 and 
11, demonstrated in vitro growth curves nearly identical to that of null-transduced cells. 
Generation of the pCLNC-IP10 retroviral construct and stable transduction of 
A375 human melanoma Cells 
The TA/IP-10 cloning vector was digested with BamHI (New England Biolabs, 
Beverly, MA), filled in using Klenow fragment (Life Technologies) and digested 
with Hindlll. The IP-10 construct was gel purified and cloned into the multiple 
cloning site of the retroviral vector pCLNCX7 , (obtained from Dr. P. Robbins, 
National Cancer Institute) to generate the vector pCLNC-IP1 0 (Fig. 1 a). 
Retrovirus production and target cell transduction was carried out as previously 
described8. Briefly, replication-incompetent pseudotyped retroviruses were 
generated by cotransfecting the packaging cell line 293GP (Dr. P. Robbins) with 
pCLNC-IP10 or pCLNCX and the plasmid pMD.G (Dr. P. Robbins), containing the 
G protein gene from vesicular stomatitis virus9. The A375 human melanoma cell 
line (American Type Culture Collection, Manassas, VA) was transduced with 
pCLNCX- or pCLNC-IP1 0-derived retrovirus in the presence of hexadimethrine 
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bromide (8 g/ml; Sigma, St. Louis, MO) and selected in G418 (400 g/ml; Life 
Technologies). IP-1 a-transduced clones were selected by plating transduced 
cells in limiting dilution. 
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Figure 2 Subcutaneous tumor growth after injection of parental A375 cells, null-transduced cells 
and IP-10-transduced clones 2 and 11 (n=·7 mice per group). The growth of both clones was 
significantly inhibited compared to the control tumors (p=0.0002). 
Western blotting 
Clones were plated in 6-well plates at a density of 1 06/well in complete medium, 
consisting of Modified Eagle's Medium with 1 0% fetal calf serum, 4 mM 
glutamine, 4 mM pyruvate and supplemental vitamins (Biofluids, Rockville, MD). 
After overnight incubation at 3rC, the medium was replaced with 1.0 ml of fresh 
medium. After 24 hr incubation, supernatants were harvested and centrifuged at 
860g. Equal volumes from the supernatants were mixed with loading buffer and 
separated by gel electrophoresis under reducing conditions (1 0% Bis-Tris; 
NuPAGE, Novex, San Diego, CA). Medium alone was used as a negative control 
and recombinant human IP-10 (R&D Systems) was used as a positive control. 
The gel was transferred to a nitrocellulose membrane (Novex) and the membrane 
was blocked with 5% milk in Tris-buffered saline, pH 7.4 (TBS) for 6 hr at 4°C. 
The membrane then was probed with goat anti-human IP-10 polyclonal antibody 
(0.2 g/ml, diluted in TBS with 5% milk; R&D Systems) overnight at 4°C. The 
membrane was washed in TBST and incubated with HRP-conjugated donkey 
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anti-goat secondary antibody (diluted 1:10,000 in TBS/1.5% BSA; R&D Systems) 
for. 1 hr. After washing in TBST, detection was performed using the ECL 
chemoluminiscence detection kit (Amersham Pharmacia Biotech, Uppsala 
Sweden). 
Proliferation assay 
IP-1 0- or null-transduced cells were plated in type I collagen-coated 96-well 
plates (Biocoat, Becton Dickinson) at a density of 1,000 cells/well and incubated 
at 3rC in complete medium. Proliferation was analyzed daily for 4 days by WST-
1 assay (Boehringer Mannheim, Indianapolis, IN) according to the manufacturer's 
instructions. Eight samples in each group were tested. The degree of proliferation 
was expressed as the absorbance at 450 nm (A450) measured in a Multiskan 
MCC/340 plate reader (Titertek, Huntsville, AL). 
Tumor formation by retroviral/y transduced cells 
Animal experiments were conducted according to protocols approved by the NIH 
Animal Care and Use Committee. Eight-week-old female nude mice (Charles 
River Laboratories, Wilmington, MA) were injected with 2 x 106 parental A375 
cells, null-transduced cells, IP-1 0 clone 2 cells or IP-1 0 clone 11 cells. 
Subcutaneous (SQ) injections were administered in the right flank in 100 L PBS. 
Each group consisted of 7 animals. Tumors were measured in 2 dimensions 
using calipers at regular intervals by a blinded observer (M.M.) and tumor 
volumes were calculated according to the formula: volume = width2 x length x 
0.52. 
To evaluate the ability of IP-1 a-transduced cells to inhibit the growth of 
neighboring non-IP-1 0-transduced cells (paracrine effect), IP-1 0 clone 2 cells 
were combined with null-transduced cells in vitro to yield mixtures containing 
100%, 50%, 25%, 12.5% and 0% clone 2 cells. Mice were injected as described 
above with 2 x 1 06 mixed cells. Each group consisted of 8 animals. Tumors were 
measured as described above. 
Immunohistochemistry and histopathologic evaluation 
Tumors were harvested immediately after animal sacrifice by cervical dislocation 
and fixed in 10% buffered formalin. Tissue blocks were paraffin embedded within 
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48 hr and sectioned at 5 m. Sections were stained with hematoxylin and eosin 
(H&E) or antibodies specific for von Willebrand factor (vWF; DAKO, Carpinteria, 
CA), proliferating cell nuclear antigen (PCNA; PharMingen, San Diego, CA) or 
caspase-3 (PharMingen). For immunostaining, sections were deparaffinized in 
xylene and hydrated in decreasing concentrations of ethanol. After endogenous 
peroxidase activity was blocked using 3% hydrogen peroxide in methanol for 10 
min, sections were incubated for 1 hr in blocking solution containing 10% normal 
goat serum. Sections were incubated in primary antibody at 4oc overnight. Slides 
then were washed, incubated in biotinylated species-appropriate secondary 
antibody for 1 hr and exposed to avidin-biotin-peroxidase complex (Vector 
Laboratories, Burlingame, CA). Sections were reacted with 0.06% 3,3 DAB 
(Sigma) and counterstained with hematoxylin. 
H&E and immunostained sections from the tumors with the 4 median volume 
measurements in each group were analyzed by a pathologist (S.H.) blinded to 
the identity of the groups. Only good-quality sections with uniform, well-
demarcated staining and low background were analyzed. Microvascular density 
of each tumor was calculated as the mean number of vWF-positive microvessels 
per high-power field (hpf, 600x total magnification) based on a minimum of 5 
hpfs. Mitoses similarly were counted as numbers of cells with nuclei staining 
positively for PCNA per hpf. Apoptosis was evaluated based on the presence of 
cells staining positively for caspase 3, according to the following scoring system: 
1, n·o apoptotic cells; 2, rare, isolated apoptotic cells; 3, scattered apoptotic cells 
(1-2/hpf); and 4, clustered or numerous apoptotic cells (>2/hpf). 
Statistical analysis 
Data are presented as the mean ± SE. Comparisons between groups were 
performed using the Mann-Whitney U test or Kruskai-Wallis test, where 
appropriate. Two-tailed p-values <0.05 were considered significant. 
RESULTS 
In vitro characteristics of parental and transduced A375 cells 
Western blotting of supernatants from IP-1 0-transduced clones revealed bands 
with electrophoretic mobility equal to that of recombinant human IP-1 0 (Fig. 1 b). 
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These bands were absent in supernatant from parental or null-transduced A375 
cells. Of the clones tested, supernatant samples from clones 2 and 11 
demonstrated the densest bands on Western blot. These high-expressing clones 
demonstrated in vitro growth characteristics nearly identical to those of null-
transduced cells (Fig. 1c). 
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Figure 3 Growth of tumors resulting from injection of mixtures of IP-10-transduced clone 2 and 
null-transduced cells. Each group of animals received a total of 2 x 106 cells, consisting of varying 
proportions of IP-10-transduced cells (n=S mice per group). Tumor growth correlated inversely 
with the fraction of IP-10-transduced cells injected. A mixture containing 50% IP-10-transduced 
cells demonstrated significant growth inhibition when compared to null-transduced tumors (p = 
0.003 at day 40). 
In vivo growth of parental and transduced A375 cells 
By 28 days after injection, animals bearing subcutaneous parental or null-
transduced A375 melanoma had tumor volumes of 1,100 ± 185 and 848 ± 227 
mm3, respectively (Fig. 2). Tumor volumes in animals injected with IP-1 0 clones 2 
and 11 were 47 ± 31 and 124 ± 37 mm3, respectively (p = 0.0002, Kruskai-Wallis 
test). Similar differences in growth · were observed in multiple, independent 
experiments. The difference in growth of clones 2 and 11 was not statistically 
significant (p = 0.09 at day 28, Mann-Whitney U test). 
The size of subcutaneous tumors resulting from the injection of a mixed 
population of cells correlated inversely to the fraction of IP-1 0-transduced cells 
present (Fig. 3). By day 40 after injection, tumors consisting of 50% IP-1 a-
transduced cells were significantly smaller than tumors consisting of null-
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transduced cells only (371 ± 112 mm3 vs. 1241 ± 178 mm3 , respectively; p = 
a.aa3, Mann-Whitney U test). At this time, tumors consisting of IP-1 a-transduced 
cells only were 88 ± 45 mm3 . 
Histopathologic findings 
H&E-stained sections of control (null-transduced) tumors demonstrated large 
areas of confluent tumor cells with zones of central necrosis (Fig. 4A). IP-1a-
transduced tumors were considerably smaller and had confluent central areas of 
necrosis surrounded by a thin rim of viable tumor cells and a fibrotic capsule (Fig. 
48). Immunohistochemical staining for von Willebrand factor demonstrated well-
formed networks of capillaries surrounding nests of tumor cells in the control 
tumors (Fig. 4C). In contrast, the IP-1a-transduced tumors demonstrated only 
rare, isolated microvessels (Fig. 40). 
Microvessel counts for both clone 2 and clone 11 tumors (5.7 ± 1.6 and 4.2 ± a.4 
microvessels/hpf, respectively) were significantly lower than those for null-
transduced tumors (65.6 ± 9.2 microvessels/hpf; p < a.a5)(Fig. 5a). Similarly, 
mitotic counts for clone 2 and clone 11 tumors (3.1 ± a.5 and 2.1 ± 1.2 
mitoses/hpf, respectively) were significantly lower than those for null-transduced 
tumors (6.3 ± a.9 mitoses/hpf; p < a.a5). Apoptosis scores based on caspase-3 
immunostaining did not differ between IP-1 a-transduced and control tumors 
(mean score, 1.5 in each group). 
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Figure 4 Histologic characteristics of null-transduced and IP-10-transduced melanoma xenografts. 
(A) H&E-stained control tumors showed large areas of confluent tumor cells, with zones of 
necrosis. (B) At the same magnification, IP-10-transduced tumors appeared markedly smaller 
with central areas of necrosis surrounded by a thin rim of viable tumor cells. (C) Staining for von 
Willebrand factor (brown reaction product) revealed well-formed networks of capillaries 
surrounding nests of tumor cells in the control tumors. (D) At the same magnification, IP-10-
transduced tumors revealed only occasional, isolated microvessels. Original magnification x50 
(A,B); x400 (C,D). [Normal View 100K I Magnified View 230K] 
DISCUSSION 
The demonstration that tumors require neoangiogenesis for sustained growth 1 
has prompted intense investigation into the inhibition of tumor angiogenesis as a 
strategy for treating cancer patients. More than 40 endogenous inhibitors of 
angiogenesis have been described2. One of these, interferon-inducible protein 10 
(IP-10), was first described as a chemokine induced by interferon- (IFN-) in U937 
lymphoma cells5. IP-10 subsequently was shown to demonstrate thymus-
dependent antitumor properties 10 and to be a chemoattractant for monocytes and 
T lymphocytes3 . Studies in athymic mice4 demonstrated that IP-10 inhibited 
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angiogenesis in vivo, despite lacking .an effect in conventional in vitro assays of 
endothelial cell growth, attachment and migration. 
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Figure 5 Microvessel and mitotic counts in control and IP-1 a-transduced tumors. (A) Microvessel 
counts in IP-10-transduced clone 2 and clone 11 tumors were markedly less than those in control 
tumors, based on von Willebrand factor immunostaining (Fig. 4C,D). (B) Similarly, mitotic counts 
in the IP-10-transduced tumors were significantly lower than in control tumors, based on 
immunostaining for proliferating cell nuclear antigen (PCNA). *, p < 0.05 vs. null-transduced 
tumors. [Normal View 100K I Magnified View 230K] 
Previous preclinical studies of IP-1 0 gene therapy have investigated the use of 
adenoviral vectors. Narvaiza et a/. 11 demonstrated that an adenovirus carrying 
the IP-1 0 gene had synergistic immunologic and antitumor effects when 
combined with an adenovirus carrying the interleukin (IL-) 12 gene; however, the 
IP-1 0 vector did not inhibit macroscopic tumor growth when administered alone. 
Regulier et a/. 12 demonstrated rejection of 816 melanomas in immunocompetent 
mice after combined intravenous and intratumoral injection of an adenovirus 
containing the IP-1 0 gene but not after intratumoral treatment only. 
Advantages of using gene-therapy approaches in the antiangiogenic treatment of 
cancer include obviating difficulties with the manufacture and in vitro stability of 
recombinant proteins, reducing the need for chronic administration and possibly 
achieving greater efficacy through continuous elevation of circulating protein 
levels rather than the peak/trough kinetics of bolus protein administration2. Genes 
such as that for IP-10 are particularly attractive because they confer immunologic 
antitumor properties as well as antiangiogenic effects in preclinical models. The 
previously described adenoviral studies demonstrate the potent effects that might 
be achieved in a clinical setting of IP-10 gene therapy of cancer. 
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We carried out the present series of experiments with 3 goals. First, we wished to 
investigate the efficacy of retroviral I P-1 0 gene delivery, given concerns regarding 
toxicity associated with systemic delivery of adenovirus in humans. Second, we 
sought to determine whether antitumor effects could be directly correlated with 
evidence of antiangiogenic activity in the inhibited lesions, as the distinction 
between antiangiogenic and immunologic effects in previous gene therapy 
models has been difficult. Finally, since current gene delivery approaches cannot 
be expected to result in transduction of 100% of target cells, we investigated 
whether IP-1 0 gene delivery could affect neighboring, non-IP-1 0-transduced 
tumor growth (paracrine effect). 
We selected a human melanoma xenograft model for this series of experiments. 
Because properties of multifunctional human and murine cytokines may differ, it 
is important to demonstrate efficacy of the delivery of human genes in human 
tumor models whenever possible. In addition, melanoma patients are among 
those most likely to benefit from immunologic antitumor effects in clinical trials 13. 
Finally, the use of athymic mice allows the analysis of antiangiogenic effects of 
gene delivery independent of effects mediated by T lymphocytes4·10. 
We first demonstrated successful transfer of the IP-1 0 gene into A375 melanoma 
cells and secretion of the protein product into the cell supernatant by Western 
blot. Two clones demonstrating high IP-1 0 expression were selected for in vivo 
experiments to lessen the probability that observed effects might be due to clonal 
variation rather than IP-1 0 itself. Both clones demonstrated marked growth 
inhibition in vivo when compared to parental or null-transduced cells. This effect 
could not be attributed to differences in in vitro growth characteristics. 
Furthermore, in vivo growth inhibition was associated with a potent 
antiangiogenic effect, assessed by analysis of microvascular density. We 
therefore conclude that retroviral IP-1 0 gene transfer has antitumor efficacy 
associated with inhibition of angiogenesis. 
To adapt this model to the clinical setting, 2 general strategies might be used. 
One would be in vivo transduction of tumor cells, which has been demonstrated 
in preclinical antiangiogenic gene therapy models using injection of retroviral 
packaging cells14-17. This strategy presently cannot be expected to result in 100% 
transduction efficiency and thus some paracrine effect would be required to 
expect clinical benefit from such an approach. The other strategy would be to 
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transduce normal autologous cells ex vivo, then adoptively transfer them to the 
host. This strategy first was safely employed with T lymphocytes in humans 18 and 
has had antitumor efficacy using fibroblasts in an antiangiogenic model of 
peritoneal cancer in mice 19. Success of this strategy would also depend on a 
paracrine effect to inhibit the growth of nearby disease. 
To determine the effect of IP-1 0 gene transduction on neighboring cells, we 
injected mixtures of IP-1 0-transduced and null-transduced cells and observed the 
resultant tumor growth characteristics. Inhibition of tumor growth increased with 
increasing fractions of IP-1 0-transduced cells; tumors consisting of 50% IP-1 0-
transduced cells demonstrated significant growth inhibition sufficient to conclude 
that gene delivery to every tumor cell is not required for efficacy. It should be 
noted, however, that the presence of a paracrine effect is not the only condition 
necessary for translation of retroviral antiangiogenic gene therapy to the clinical 
setting. For example, if ex vivo transduction of autologous cells were used, these 
transduced cells either would need to produce sufficient gene product to elevate 
circulating cytokine levels, or would need to be able to target the tumor 
specifically. In addition, our current understanding of tumor angiogenesis 
suggests that production of the therapeutic protein would need to persist for 
prolonged periods of time to be of clinical benefit. Clearly, ongoing investigation 
of retroviral gene-therapy approaches to improve the amount, duration and tumor 
specificity of gene expression is warranted. 
In conclusion, our data demonstrate that retroviral delivery of the human IP-1 0 
gene results in secretion of protein sufficient to inhibit angiogenesis and tumor 
growth in vivo and that the resultant antitumor effect is conferred to neighboring, 
non-IP-10-transduced cells. These results suggest that IP-10 gene therapy 
models utilizing in vivo retroviral transduction of tumor cells or adoptive transfer of 
autologous cells transduced ex vivo might be effective in the clinical setting. 
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EMAP II in TNF-based anticancer therapy 
ABSTRACT 
In 1990 Clauss et a/. first reported on a 44-kDa polypeptide, later called 
Endothelial Monocyte Activating Polypeptide II (EMAP II). This protein was 
discovered in the supernatant of Meth-A fibrosarcoma cells and had shown to 
enhance the induction of the procoagulant Tissue Factor (TF) on endothelial 
cells. Besides upregulation of TF mRNA, EMAP II increases cellular receptors for 
TNF on endothelial cells, which is likely to enhance the predisposition of tumors 
to undergo thrombosis and hemorrhagic necrosis, once challenged with TNF. 
This feature enables EMAP II to upregulate TNF sensitivity of TNF-resistant 
tumors, an observation of importance in developing new approaches aimed at 
improving the efficacy of the use of TNF as an anticancer treatment. 
We describe the potential additional effects of EMAP II, when used in 
combination with TNF, with regards to antitumor activity in the Isolated Limb 
Perfusion (ILP) setting. In addition we describe our experimental data in human 
sarcoma, which also supports this hypothesis. 
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INTRODUCTION 
Angiogenesis, formation of new vessels from the endothelium of the preexisting 
vasculature, is a key element in a large number of normal and pathologic 
processes 1. When focusing attention on pathologic processes the contribution of 
angiogenesis can be demonstrated to play a crucial role in tumor development. 
Studies from Folkman2 and other groups3 have proven that production of pro-
angiogenec factors by tumor cells is a prerequisite for tumor growth beyond a 
certain size, ranging from 0,2 mm diameter (in murine lung metastasis models) to 
a maximum of 2 mm diameter (in an a-vascular chondrosarcoma in the rat)4. 
Along with this finding it is known that tumors with greater capability to develop 
neovasculature are more lethal by means of growth velocity and metastatic 
potential5-12. These observations have further strengthened the idea that 
antiangiogenic compounds may supply an additional treatment to slow down or 
inhibit the growth of primary solid tumors and their metastasis 13-15. 
Neovascularisation of a tumor requires that a tumor switches to the angiogenic 
phenotype by changing the balance of angiogenesis inducers and countervailing 
inhibitors 16 . At least two general mechanisms are recognized: (1) angiogenic 
activity arises from the tumor cells themselves by releasing angiogenic 
molecules; (2) angiogenic activity arises from host cells recruited by the tumor 
(e.g. macrophages) by mobilizing the extra-cellular matrix and requiring 
concomitant loss of physiological inhibition of endothelial cell proliferation. The 
mechanism underlying shifts in the balance between all angiogenic regulators 
remain not fully understood. 
Malignant cells communicate with their surrounding tissue and matrix by means 
of a large variety of signals that they produce. lnterleukines, CAM's (Cellular 
Adhesion Molecules), chemokines, integrines, proteases and receptors can all 
exert an effect on stroma, tumor matrix, tumor vasculature and pre-existing 
vasculature. This fast expanding list of pro- and antiangiogenic factors supports 
the hypothesis that the tumor itself is responsible for the process of angiogenesis. 
Cytokines from various sources are released in the vicinity of the tumor in 
response to hypoxia or ischaemia, and can rapidly initiate angiogenesis. Tumors 
can produce a large number of cytokines 17, all of them having different functions 
in the regulatory pathway of angiogenesis. Some have mitogenic effects on 
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endothelial cells, others have chemotactic activity or induce tube formation or 
even have multiple functions. Some cytokines are chemotactic for macrophages, 
infiltrate the tumor and stimulate secretion of more angiogenic cytokines. There is 
hope that these cytokines will be of major importance in the next decade in the 
field of antiangiogenic therapy. Therapies based on antiangiogenic strategies 
aimed at malignancies continue to evolve and clinical trials are been conducted18. 
More than a decade has passed since Clauss 19 first described an unique cytokine 
that was excreted by certain tumors, called EMAP II by later authors20. Here we 
will discuss the role of this cytokine, its antiangiogenic properties and the possible 
co-existing impact on vascular damage when combined with TNF leading to 
destruction of established tumors and inhibition of tumor growth. 
TNF AND THE ISOLATED liMB PERFUSION 
TNF is one of the cytokines currently used as an anticancer therapy. The 
systemic administration of TNF in cancer patients is associated with dose-liming 
toxicity already at low and ineffective doses without antitumor effects. The 
effective delivery of high concentrations of TNF in the clinic was pioneered by 
Lejeune and Lienard with the application of TNF in isolated limb perfusions in 
1988, and led to a report of high complete responses in melanoma and sarcoma 
patients21 . In a multi-center European trial, ILP with TNF and melphalan (with22·23 
or without22 IFN-gamma) resulted overall in a 76% response rate and a 71% limb 
salvage rate in patients with limb-threatening soft-tissue sarcomas24. TNF-based 
ILP has been established as a highly effective new method of induction 
biochemotherapy in extremity soft tissue sarcomas with a 20-30% complete 
remission (CR) rate and an approximate 50% Partial Remission (PR) rate. On the 
basis of these results in the multi-center program TNF was approved and 
registered in Europe in 1998. In the mean time TNF-based ILP programs for limb 
salvage have been commenced in more than 30 cancer centers in Europe22. High 
dose TNF destructs tumor vasculature and it increases tumor-selective drug 
uptake (e.g. melphalan, doxorubicin) 3- to 6-fold25•26. This latter observation 
makes it of critical importance to have as many TNF receptors as possible on the 
target tumor endothelium. Existing experimental data in animal studies suggest 
that EMAP II may add to this requirement. 
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EMAP II: IDENTIFICATION AND BACKGROUND 
Endothelial Monocyte Activating Polypeptide II (EMAP II) is a cytokine first 
identified as a tumor cell secreted protein when it was isolated from the 
supernatant of a murine methylcholantrene A (meth-A) fibrosarcoma27•28. 
Based on the diversity in responses of tumors to TNF together with the fact that 
the TNF actions seem to be vasculature-mediated, the search for soluble 
mediators secreted by neoplastic cells was started. Kao et a/.27 focused on the 
Meth-A tumor cells, a tumor sensitive to TNF in vivo, but TNF-resistant in vitro29 . 
By directing a pilot study to possible factors influencing this effect they found 2 
polypeptides in the supernatant of Meth-A tumor cells that modulated monocyte 
function in vivo, leading to the acronym EMAP I and II. The latter soon proved to 
be the most potent in influencing the TNF-mediated thrombosis in tumors30 . 
EMAP II mRNA and the corresponding precursor protein, proEMAP, are 
constitutively expressed and produced by all cell types analyzed in vitro, whereas 
the mature cytokine is only present in the supernatant of apoptotic cells31 . EMAP 
II {or Meth-A factor) is an approximately 18 kDa pro-inflammatory cytokine, 
synthesized as a precursor protein lacking a conventional secretion signal 
peptide28. Despite the cytokine activity of the mature EMAP II, no sequence 
homology is found based on amino-acid sequence with any other known 
cytokine32. The sequence of several proEMAP-related proteins however, 
suggests that the p43 component of the amino acryl-tRNA multienzyme 
synthetases complex is the precursor of the active mature cytokine33 • Aminoacyl-
tRNA synthetases are proteins that catalyze the activation their cognate amino 
acids and transfer to the relevant tRNA. This complex consists of a subset of 9 
synthases all specific for their own amino acid, together with three auxiliary 
proteins34. One of those three auxiliary proteins turned out to be proEMAP35. 
Wakasugi has shown36 that human full-length Tyrosyl-tRNA synthetase (TyrRS), 
which normally resides in the cell cytoplasm, was secreted by a human 
hematopoietic cell line that had been triggered by serum deprivation. TyrRS is 
inactive as a cell-signaling molecule but intracellular TyrRS has enzymatic activity 
and after cleavage into two fragments by extra cellular proteases both fragments 
surprisingly appear to have retained their cytokine activity. The carboxyl-terminal 
fragment happens to show some homology with EMAP II, and is able to stimulate 
130 
EMAP II in TNF-based anticancer therapy 
leukocyte and monocyte chemotaxis, to induce myeloperoxidase, and to excite 
tissue factor and tumor necrosis factor synthesis. The amino-terminal fragment 
behaves like the cytokine IL-8, yet still retains complete TyrRS activity. This and 
other findings established the fact that the precursor of EMAP II is a multi-
functional protein that assists in protein synthesis in normal cells. Upon apoptosis 
it is released as functional cytokine, linking cell viability to programmed cell 
death37. 
The mechanism of cleavage and secretion of EMAP II has been controversial. 
Knies et a/. suggested that the coordinate program of cell death includes 
activation of a caspase-like activity that initiates the processing of a cytokine 
responsible for macrophage attraction to the sites of apoptosis38. This same 
group of researchers soon identified with in vitro experiments that caspase-7, and 
to a lesser degree caspase-3, is capable of cleaving proEMAP to a fragment 
corresponding to mature EMAP 1139. However Zhang and Schwarz, who could 
not manage to get the proEMAP cleaved by caspases-3 or -7, speak against 
these results40 . They suggest a more important function for EMAP II with regard 
to induction of apoptosis, and are currently focusing on the protease that can be 
held responsible for the cleavage. The presence of apoptosis seems to correlate 
with posttranslational processing of EMAP II, which may explain apoptosis-
induced influx and sequestration of leukocytes in the reperfused kidnel1. More 
research should be done to point out the exact relation between EMAP II and 
apoptosis. 
EMAP II: ACTIONS AND FUNCTIONS 
Cells undergoing apoptosis are rapidly removed by monocyte-derived 
macrophages, suggesting a contemporaneous release of factors with leukocyte 
and monocyte chemotactic activity. EMAP II has shown to be a cytokine that 
recruits monocytes and macrophages in areas with apoptosis for scavenging 
apoptotic corpses. This tumor-derived cytokine has potent effects on endothelial 
cells42. 
The interest in our lab for EMAP II was sparked by observations of Wu eta/. that 
upregulation of EMAP II can render a previous non-responding tumor sensitive to 
TNF treatment43 . This research group demonstrated that by over-expressing 
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EMAP II in a TNF-resistant human melanoma line by retroviral-mediated transfer 
of EMAP II eDNA, the tumor becomes TNF-sensitive in vivo, but not in vitro. A 
possible explanation for this is that TNF acts on the vasculature, which, after 
being primed by EMAP II, eventuates in an upregulation of TNF-R1 and TF 
expression on the endothelial cells. This mechanism will not be present in vitro 
cell cultures of tumor cells44. TNF acts through two distinct cell-surface receptors 
of 55 kDa (TNF-R1) and 75 kDa (TNF-R2), which are ubiquitously expressed45 . 
The receptors utilize both dependent and shared intracellular signaling pathways 
to mediate a variety of effects on cells, some of which are receptor specific. 
Cytotoxic effects of TNF are mediated by TNFR-1, whilst TNF-R2 has 
proliferative effects, as for example in lymphoid cells46 . TNF-R1 expression may 
be associated with the induction of endothelial cell apoptosis by TNF. Therefore, 
EMAP II produced by tumors may, at least in part, determine in vivo sensitivity to 
TNF by up-regulating TNF-R1 expression on endothelial cells, triggering cell 
death in the presence of TNF leading to eventual ischaemic necrosis of the 
tumor. In vitro studies of Liu47 show an EMAP 11-like mediated cytotoxicity and 
apoptosis of corneal endothelial cells. This effect was even more profound after 
adding cycloheximide, a protein synthesis inhibitor. 
An increase of secretion of active EMAP II by a tumor leads also to an 
upregulation of TF on the surrounding endothelial cells, providing another link 
between EMAP II and TNF as used in an ILP, where it frequently results in 
hemorrhagic necrosis of the tumor. This upregulation will lead to an increased 
pro-coagulant activity, and also a more permeable vasculature. Friedl et a/. have 
found another explanation for the effects on tumor vasculature48 . They 
demonstrated that TNF only exerts its permeability and procoagulant activity 
when TF expression on cell surface is combined with extrinsic clotting factors in 
plasma. 
OUR DATA 
We have demonstrated that in vitro stable transfection of rat sarcoma cells led to 
an upregulation of endogenous pro-EMAP II in these tumor cells. This gene 
transfer induced sensitivity to subsequent regional TNF treatment by means of an 
isolated limb perfusion (ILP) in rats. To confirm that this was indeed an EMAP II 
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effect, tumor bearing rats were pre-treated with an intravenous injection of 
recombinant EMAP II followed by an ILP with TNF. These experiments resulted 
in a comparable tumor response as observed in the rats undergoing EMAP II 
gene therapy followed by TNF ILP49. 
Table 1 - Tumor volume (mm3) in rats on consecutive days after sham or TNF isolated 
perfusion. 
0 2 4 6 8 10 12 14 
Wild type 
Sham 622 1210 2156 3299 
TNF 617 1134 1740 2967 3752 
Transfected 
Sham 713 846 1569 2941 5107 
TNF 532 589 1184 1877 2159 2381 3322 5220 
Table 1 and Figure show results of TNF ILP in rats bearing the transfected 
tumor compared to the wild type tumor. Perfusion with Haemaccel alone resulted 
in progressive disease in all animals. Although ILP with TNF resulted in a slight 
inhibition of tumor growth of the wild type BN tumor compared with the sham 
control, there was no significant difference in tumor response. As can be seen in 
this graph the EMAP II transfected tumor BN-E responded significantly better to 
ILP with 50 !lg TNF. We saw macroscopically a more profound necrosis in the 
BN-E tumor that led to a significant slower outgrowth of tumor after the perfusion. 
Even in animals with transfected tumors a small rim of viable tumor cells 
survived. However as can be seen at day 9, the overall observed response rate 
still implied a decline in tumor dimension, while profound recurrent tumor growth 
was demonstrated in all animals from day eleven. 
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Figure 1 Growth curves of BN tumor after ILP with sham (111) n=5; or TNF ( +) 
n=7; BN-E tumor after ILP with sham (o) n=7; or TNF (LI.) n=5. 
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EMAP II- POTENTIAL CLINICAL IMPLICATIONS 
Pharmacological administration of EMAP II as a neo-adjuvant therapy prior to 
TNF will not take place before complete elucidation of the mechanism of 
activation of the mature protein. Since the relative expression of EMAP II likely 
may correlate with a tumor's sensitivity to TNF based on a dose-dependent 
increase of TNF receptor on endothelial cells, high EMAP II levels must be 
obtained before treatment with TNF. Intended effects will be the upregulation of 
TF on tumor endothelial cells leading to massive thrombosis at the place of the 
vascular damage. This combined with an increased amount of TNF receptors will 
intensify the action of administered TNF, and as a result to this necrosis of tumor 
vasculature an increased port d'entn§e for melphalan or other chemokines. 
At this moment the approved use of TNF in Europe is restricted to the Isolated 
Limb Perfusion setting where TNF is combined with melphalan for unresectable 
soft-tissue sarcomas to facilitate limb salvage50 . Furthermore TNF is used 
successfully in this setting treating a great variety of tumors such as melanoma, 
drug resistant recurrences of bony sarcomas, squamous cell carcinomas, merkel 
cell carcinomas and others50 . 
All these studies have greatly increased the understanding of the way in which 
TNF works. As a consequence of its toxicity when administered systemically, 
techniques like the isolation of limbs and organs have been developed. At 
present we hope that EMAP II can be valuable in potentiating the effect of TNF. 
By hypothesizing that a higher EMAP II concentration in the surroundings of a 
tumor, either by systemic injection, gene therapy, or other modalities, will lead to 
a profound response to TNF treatment, perhaps a diminished dose of TNF might 
be enough to induce the same clinical responses. So far this hypothesis can not 
be validated by clinical data. 
We have used immunohistochemistry to analyze the expression of EMAP II in 
sarcoma of 18 patients that had been treated with TNF and melphalan in an ILP, 
in order to estimate the predictive value of EMAP II expression. From a large 
database of patients treated with an ILP with TNF and melphalan we selected 
two patient groups with identical demographic characteristics and equal grade 
and histologic classification of their soft tissue sarcomas. Patients in the first 
group responded with a complete response or partial response, with over 50% 
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tumor necrosis; patients in the second group responded with progressive 
disease, no change, or a partial response with less than 25% tumor necrosis. 
Biopsies from defined morphologic areas of paraffin embedded tumors were 
analyzed by immunohistochemistry with EMAP II antibody, vascular endoth.elial 
growth factor (VEGF) antibody, CD34 antibody as a vascular marker and MIB-1 
antibody to determine proliferative indices; these characteristics were compared 
to patient outcome concerning response rates. A promising good correlation was 
found between the extent of EMAP II expression in the tumors and the response 
of the patient. Table 2 demonstrates a showed great diversity between the 
tumors regarding EMAP II expression, with a preference to a high intensity in the 
group of patients with a CR, and a much lower expression of EMAP II in the NC 
group. However throughout these experiments data was published that 
immunohistochemistry with EMAP II would mark as well pro-EMAP as the mature 
and active form of EMAP II. This data implied that our initial conclusion could no 
longer be sustained. Currently we are conducting a prospective study to 
determine EMAP II expression in tumors by means of Western Blot. With this 
method we will be able to distinguish between pro- and mature EMAP II and we 
will be in the position to answer the question. Until then we have no rationale to 
reject the hypothesis, however clinical evidence still lies ahead of us. 
Table 2 -Score staining intensity 
Score CR group Score NC Group 
(n=9) (n=9) 
VEGF 2.8 2.7 
EMAP II 3.2 1.5 
MIB-1 2.0 2.5 
CD34 3.6 3.5 
Currently studies are directed to the exact cleavage proteases, the profile of the 
receptor on endothelium, effects of EMAP II on normal cells and expression 
patterns of EMAP II in tissue of patients treated with TNF. Also more research 
needs to be done in order to define possible side effects of EMAP II, since 
cytokines have shown to provoke numerous. 
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SUMMARY 
The action of EMAP II in cancer is complex, just as is the case for cytokines such 
as IL-1~ and TNF-a. Endogenous EMAP II chronically produced in the tumor 
microenvironment enhances the antitumor properties of TNF in an ILP. Moreover 
EMAP II is a crucial effector molecule in apoptosis, it shows chemotactic 
properties, and it is capable of upregulation proteins on endothelial cells like TF 
and TNF-R1. It seems that EMAP II plays a role in stabilizing vascular 
architecture by maintaining a balance in angiogenic pathways. The angiogenic 
response is governed by the interaction of angiogenic growth factors and 
cytokines with specific receptors on the endothelium, as well as the interaction of 
these cells with their surrounding matrix, which is regulated by matrix-degrading 
proteases and adhesion molecules such as integrines. A number of agents have 
been discovered and developed that aim to inhibit angiogenesis and to convert 
the tumor to a dormant state. EMAP II was identified in the process of unraveling 
the mechanism of action by which TNF exerts its tumor effect. It was discovered 
that it was produced in the TNF-sensitive Meth-A tumor. Successive experiments 
have shown that EMAP II can confer TNF resistant tumors to TNF sensitivity. 
When missing links are elucidated and some controversies about EMAP II are 
cleared future studies are justified where EMAP II will be administered as a 
neoadjuvant or priming therapy, concurrent with or prior to TNF administration. 
By exploring these routes of multiple-therapy an increased understanding of the 
balance between proangiogenic and antiangiogenic agents will be obtained. 
Therapies that have proven to be effective in animal studies will in future studies 
have to demonstrate whether this is also true in man. 
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SUMMARY 
Surgery represents the principal treatment of all resectable tumors. In cases of 
wide spread local disease or metastasized sarcomas however, surgical treatment 
provides insufficient results. In those cases chemotherapeutics can be a useful 
alternative to palliate patients and in specific cases may even lead to full 
recovery. Tumor vascularisation plays a critical role in both the development and 
the treatment of cancer. High levels of vascularisation generally have a positive 
impact on chemotherapeutic results, while in the meantime this drives tumor 
growth and growth of metastases. The development of new blood vessels -
angiogenesis - is regulated by a large number of cytokines. Cytokines are soluble 
proteins, which under normal circumstances are produced by the mononuclear 
cells of the immune system. They exert influence on the immune system and 
regulate it. When produced by tumor cells however, cytokine production can lead 
to harmful interactions, such as the intensivation of angiogenesis, which can 
stimulate tumor growth. 
Effective treatment of solid tumors like sarcomas, as described in this thesis, is 
hampered by specific tumor properties and the side effects of the treatment. 
Present chemotherapeutics do not seem to be very effective and lead to tumor 
resistance, while causing significant toxicity. Therefore alternative therapies are 
required for this group of patients. In this context the isolated limb perfusion (ILP) 
with tumor necrosis factor (TNF) and melphalan has proven to be a successful 
therapy for the treatment of melanoma and sarcoma. An isolated perfusion 
creates a closed system in which high dose chemotherapeutics can be 
administered locally, without risking systemic toxicity. TNF is a cytokine which 
can bind to tumor endothelium and cause local hemorrhagic necrosis of the 
tumor, provided that high enough concentrations are reached. This necrosis 
arises from extended damage of the endothelium through which cytostatics such 
as melphalan can enter the tumor cell. 
To further improve the response to this therapy it is essential to gain a better 
understanding of how sarcoma growth takes place and to develop new 
chemotherapeutics. 
This thesis describes our results with the partly experimental treatment of 
. irresectable sarcoma based on the use of a combination of drugs. Our hypothesis 
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was that the addition of a new cytokine, Endothelial Monocyte Activating 
Polypeptide (EMAP II), to the existing combination of TNF and melphalan in the 
perfusion circuit would lead to an improved clinical response. The aim of the 
clinical studies and laboratory experiments in this thesis is to investigate the 
mechanisms around TNF and to develop methods to improve TNF-based 
therapy. 
In Chapter 1.1 a short overview is given on previous results with TNF using the 
ILP technique. The aim of the present study is described, namely to obtain insight 
in the way in which TNF influences tumor endothelium. In this section we 
describe several clinical studies in patients with disseminated disease and the 
development of EMAP II as a possible new adjuvant chemotherapeutic in 
combination with TNF. 
Since the contribution of TNF to the efficacy of isolated perfusion of organs has 
not yet been conclusively demonstrated, it is important to determine whether its 
use has any irreversible effects. Hence a study was conducted in patients 
undergoing an Isolated Hepatic Perfusion (IHP) to characterize the toxicity and 
secondary cytokine production attributable to TNF. The results of this study are 
described in the clinical part of this thesis, starting with Chapter 11.2. Thirty-two 
patients with irresectable colorectal cancer confined to the liver were divided in 
two groups. One group received an IHP with melphalan alone, while the other 
group underwent an IHP with melphalan and TNF. The patients who did receive 
TNF had significant higher IL-6 and IL-8 (inflammatory cytokines) levels in serum 
and perfusate during the first 24 hours after the perfusion. In addition there was 
significant systemic and regional toxicity compared to those receiving melphalan 
alone. Significant systemic (low blood pressure, high heart frequency, and low 
pulmonary pressures) as well as local (increased bilirubin levels and lowered 
platelet counts) differences were observed during the first 48 hours post-
perfusion. The most important observation however was that these effects were 
transient and did not appear to be of clinical consequence. 
The demonstration of the limited nature of TNF's side effects leaves few 
arguments against its use in ILP treatment. As TNF exercises its effects via the 
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tumor endothelium, the expectation is that highly vascularized tumors in particular 
would benefit from treatment with TNF. Chapter 11.3 describes results of 16 limb 
perfusions using TNF and melphalan in 10 patients with Non resectable Stewart 
Treves lymphangiosarcoma. Thus far amputation was the only available 
treatment for these patients, as chemo- and radiotherapy provided insufficient 
results. In our experiments we were able to prevent amputation in 80% of the 
patients, which indicates that we have developed a new treatment option. 
TNF affects tumor growth at the TNF receptors on tumor vasculature. This gave 
rise to the question whether patients with soft tissue sarcoma that were 
previously subjected to radiotherapy, and thus displaying a scarred and disrupted 
vascular bed, would still respond to treatment with TNF. In Chapter 11.4 we 
present the results of ILP treatment with TNF and melphalan in 26 patients with 
recurrent Soft Tissue Sarcoma, whose primary tumor was initially treated by 
resection followed by radiotherapy. Limb salvage could be established in 17 (65%) 
patients, who at time of their referral were considered to be candidates for 
amputation. Regional toxicity was limited and systemic toxicity minimal to 
moderate, with no toxic deaths. We concluded that ILP with TNF and melphalan 
can be performed safely and with satisfying results in patients with locally 
nonresectable recurrent soft tissue sarcoma, previously treated with radiation 
therapy (and possibly resection). 
The third section of this thesis focuses on the laboratory research conducted to 
clarify the molecular basis of the workings of TNF. Many studies have already 
demonstrated that TNF operates via the tumor endothelium. Chapter 111.5 
explains why not all tumors react equally well to TNF treatment, once more 
establishing that this is tumor endothelium dependent. It appears that tumors with 
lower levels of vascularisation, such as the colon carcinoma metastases, are less 
sensitive to TNF treatment. Through animal experiments we demonstrate that the 
concentration of chemotherapeutics in the tumor depends on the tumor 
vascularisation levels. ILPs with TNF and melphalan were performed in rats with 
three different tumors, the CC531 colon carcinoma, the ROS-1 osteosarcoma, 
and the BN-175 soft tissue sarcoma. The levels of vascularisation were 
measured through immunohistology and the Hb-assay. High concentrations of 
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melphalan were detected in the highly vascularized BN-175 tumor, compared to 
low concentrations in the less vascularized ROS-1 and CC531 tumors. The high 
melphalan concentration in the BN-175 tumor resulted in full tumor regression in 
the majority of the rats with the BN-175 tumor. 
Previous chapters already describe that tumor vascularisation is a cause of the 
large variation in patient response to isolated limb perfusion with TNF and 
melphalan. Another cause can be found by observing the cytokine production of 
the tumor itself. EMAP II is a tumor-secreted cytokine which is at least in part 
held responsible for the variations in response to TNF. EMAP II is a relatively 
newly discovered cytokine with a wide range of interactions in the area of 
angiogenesis. 
It is also known that EMAP II secretion invokes an upregulation of TNF receptors 
on the tumor endothelium. In Chapter 111.6 the question is raised whether EMAP 
II production can be increased in tumors producing only low levels of EMAP II. 
Laboratory experiments have been conducted with rat soft tissue sarcoma which 
appeared to be relatively insensitive to TNF administration. We constructed a 
tumor clone by means of retroviral transfection in which we incorporated m-RNA 
of EMAP II, thus upregulating the EMAP II expression in this tumor. We then 
used this tumor in our existing TNF based limb perfusions in rats. It turned out 
that the TNF sensitivity of this tumor in vivo was significantly increased. 
Chapter 111.7 demonstrates the feasibility of increasing cytokine production in a 
tumor by retroviral transfection. The chemokine Interferon-inducible Protein-1 0 
(IP-1 0) has antiangiogenic characteristics. By transfecting a human melanoma 
cell line with an IP-10 gen construct we tested the hypothesis that by increasing 
production of an antiangiogenic protein in a tumor the tumor growth rate would be 
reduced. We found that the vasculature in these tumors was reduced such that 
the tumor growth in an in vivo nude mouse model had decreased significantly. 
The conclusion is that it is feasible to initiate the upregulation of a gen 
expression, which subsequently leads to increased secretion of a functioning 
cytokine in vivo. This experiment also demonstrates the sensitivity of tumor 
growth to cytokines with antiangiogenetic characteristics. 
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Chapter IV.8 finally presents the general discussion of this thesis. EMAP II, a 
new cytokine with complex interactions in angiogenesis and tumor growth is 
reviewed and proposed as a cytokine with beneficial effects on tumor necrosis 
when used in combination therapy with TNF. Implications and possible clinical 
applications are discussed. 
CONCLUSIONS 
• Addition of TNF to melphalan during an isolated hepatic perfusion (IHP) 
results in a significant difference in post-IHP production of IL-6 and IL-8 in 
serum and perfusate. 
• Toxicity as a result of TNF administration after an isolated hepatic perfusion 
with TNF is mild and reversible, making TNF administration safe, provided 
that the dose does not exceed 1 mg. Above 1 mg severe toxicity can occur. 
• ILP with TNF and melphalan can lead to good clinical response rates and can 
avoid amputation in 80% of the patients with extensive irresectable Stewart 
Treves angiosarcoma and should be considered as a treatment option for this 
group of patients accordingly. 
" Recurrent disease of soft tissue sarcoma previously treated with radiation 
therapy responds virtually equally well to limb perfusion with TNF and 
melphalan as sarcomas in patients who did not receive radiotherapy. In 65% 
of the radiated patients this treatment led to the preservation of the limb with a 
good functional outcome and low morbidity. 
• Retroviral transfection of human melanomas with the antiangiogenic 
chemokine IP-1 0 invokes a functional protein secretion causing a decrease in 
tumor growth. 
• The level of tumor vascularisation predicts the intra-tumor concentration of a 
cytostatic after isolated perfusion with TNF and melphalan. 
• A higher concentration of intra-tumor melphalan highly improves the tumor 
regression. 
• The tumor sensitivity to TNF can be improved by increasing the EMAP II 
production of the tumor. 
• Our results justify the broadening of research into clinical application of EMAP 
II. 
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SAMENVATTING 
Chirurgie is de basisbehandeling van aile resectabele tumoren. lndien er reeds 
sprake is van zeer uitgebreide lokale verspreiding of gemetastaseerde tumoren, 
dan is excisie ontoereikend. In dat geval kunnen cytostatische geneesmiddelen 
een waardevolle aanvulling op palliatie vormen of zelfs gericht zijn op het 
bereiken van curatie. Zowel bij het ontstaan als bij de behandeling van tumoren 
speelt de vasculatuur van de tumor een grote rol. Een hoge mate van 
tumorvascularisatie kan het effect van chemotherapie gunstig be"invloeden, 
echter de tumor is voor zijn groei en metastasering ook afhankelijk van de 
ontwikkeling van voldoende nieuwe bloedvaten. Deze angiogenese staat onder 
regulatie van een groot aantal cytokinen. Cytokinen zijn oplosbare proternen die 
normaal gesproken door de mononucleaire cellen van het immuun systeem 
worden geproduceerd en op het immuun systeem een regulerend effect 
uitoefenen. Wanneer zij daarentegen door tumoren geproduceerd worden, 
kunnen zij tot zeer schadelijke interacties leiden, die bijvoorbeeld intensivering 
van de angiogenese veroorzaakt. 
Effectieve behandeling van solide tumoren, zoals sarcomen beschreven in dit 
proefschrift, wordt bemoeilijkt door bepaalde eigenschappen van deze tumoren 
en de bijwerkingen van de behandeling. Bestaande chemotherapie blijkt veelal 
weinig effectief en kan leiden tot resistentie van de tumor, terwijl een aanzienlijke 
toxiciteit in de patient ontstaat. Voor deze groep van tumoren zijn alternatieve 
therapieen vereist. Zo is de ge"isoleerde extremiteits perfusie (ILP) met tumor 
necrose factor (TNF) en melphalan een succesvolle therapie gebleken voor de 
behandeling van melanomen en sarcomen. Met de ge"isoleerde perfusie kunnen 
geneesmiddelen die systemisch tot toxiciteit zouden leiden lokaal in hoge dosis 
toegediend worden. TNF is een cytokine dat, mits in hoge concentratie aanwezig, 
na binding aan TNF-receptoren op het endotheel aanleiding geeft tot 
hemorrhagische necrose van de tumor. Deze necrose is het resultaat van 
uitgebreide beschadiging van de endotheelcel waardoor chemotherapeutica (b.v. 
melphalan) de tumor kunnen binnendringen. 
Een beter begrip van de groeiwijze van sarcomen, gecombineerd met de 
ontwikkeling van nieuwe chemotherapeutica, is essentieel om in de toekomst 
verbetering van de klinische respons in deze patienten te bereiken. 
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Dit proefschrift beschrijft onze resultaten met de deels experimentele benadering 
van irresectabele sarcomen op basis van het toedienen van combinaties van 
geneesmiddelen. Onze hypothese is dat het toevoegen van het nieuwe cytokine 
Endotheel Monocyte Activating Polypeptide (EMAP II) aan de bestaande 
combinatie van TNF en melphalan in het perfusie circuit een verbeterde respons 
tot gevolg heeft. In klinische studies en laboratorium experimenten wordt de 
werking van TNF, deels in combinatie met EMAP II, onderzocht en worden 
methoden voor verbetering van deze therapie ontwikkeld. 
In hoofdstuk 1.1 wordt in een korte inleiding een overzicht gegeven van de 
geschiedenis van de behandeling met TNF in de ge"isoleerde perfusie. 
Vervolgens wordt de doelstelling van het proefschrift uiteengezet, te weten het 
verkrijgen van inzicht in de manier waarop TNF het tumor endotheel be"invloedt. 
Dit wordt gedaan door middel van het beschrijven van een aantal experimentele 
behandelingen bij patienten met gedissimineerde sarcomen en de ontwikkeling 
van EMAP II als een mogelijke nieuwe adjuvante therapie in combinatie met 
TNF. 
Aangezien er nog steeds een controverse bestaat over de toegevoegde waarde 
van TNF met betrekking tot de respons bij de ge·isoleerde perfusie is het van 
belang voorop te stellen dat het gebruik van TNF geen irreversibele bijwerkingen 
in de patient tot gevolg heeft. In het klinische deel van dit proefschrift wordt in 
hoofdstuk 11.2 de additionele systemische en lokale toxiciteit, en de cytokine 
productie bij het gebruik van TNF beschreven in een groep patienten die een 
ge"isoleerde lever perfusie onderging. 32 patienten met irresectabele lever 
metastasen van een colon carcinoom werden in twee groepen verdeeld. De 
eerste groep kreeg een ge"isoleerde lever perfusie met aileen melphalan, in de 
tweede groep ondergingen de patienten een lever perfusie met melphalan en 
TNF. Het bleek dat in deze tweede groep de concentraties IL-6 en IL-8 
(inflammatoire cytokinen) in het perfusaat en in het bloed de eerste 24 uur na de 
perfusie significant hoger waren. Dit ging gepaard met een toegenomen toxisch 
profiel in deze patienten. Zowel systemisch, te weten lage bloeddruk, hoge 
hartfrequentie en verhoogde pulmonaire drukken, als op lokaal niveau met een 
bilirubine stijging en afgenomen aantal bloedplaatjes waren er gedurende 48 uur 
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postoperatief significante verschillen waarneembaar. Echter van groot belang is 
de constatering dat deze effecten tijdelijk en reversibel waren, en geen klinische 
consequentie hadden. 
Met het aantonen van de gelimiteerde bijwerkingen van het gebruik van TNF in 
de ge"isoleerde perfusie zijn er weinig argumenten tegen het gebruik van TNF. 
Aangezien bekend is dat TNF zijn werking uitoefent via het tumor endotheel, valt 
te verwachten dat met name zeer gevasculariseerde tumoren baat hebben bij 
behandeling met TNF. 
In hoofdstuk 11.3 worden de resultaten beschreven van 16 extremiteits perfusies 
met TNF en melphalan in een groep van 10 patienten die gediagnosticeerd 
waren met een irresectabel Stewart Treves lymfangiosarcoom. Tot dusver was 
voor deze patienten slechts een amputatie voorhanden als palliatieve therapie, 
aangezien chemo- en radiotherapie onvoldoende effect bewerkstelligden. Met 
onze resultaten bij 1 0 patienten ton en we aan dat wij een nieuwe 
behandelingsstrategie hebben toegevoegd, met een preventie van amputatie in 
80% in deze patienten groep. 
· Het effect van TNF op tumoren wordt gemedieerd via de TNF receptoren op de 
tumor vasculatuur. Wanneer tumoren behandeld zijn met radiotherapie is er een 
verstoorde vascularisatie in het tumor gebied met een toegenomen fibrosering ter 
plaatse. Dit gaf aanleiding tot de vraag of bij patienten die voor hun primaire 
tumor met radiotherapie behandeld waren nog een mogelijkheid bestond een 
tumor respons te verkrijgen met het gebruik van TNF. 
In hoofdstuk 11.4 wordt het gebruik beschreven van TNF en melphalan bij 26 
patienten die een lokaal recidief van een weke delen sarcoom hadden, waarbij de 
primaire tumor met excisie en vervolgens radiotherapie behandeld was. Bij de 
initiele verwijzing kwamen allen in aanmerking voor een amputatie wegens de 
uitgebreidheid van het tumor recidief. Na perfusie kon de ledemaat echter in 17 
patienten behouden blijven (65% ). Bij deze perfusie was de regionale toxiciteit 
beperkt, en de systemische toxiciteit minimaal, zonder mortaliteit. Hieruit hebben 
we geconcludeerd dat patienten met een lokaal irresectabel recidief van een 
weke delen sarcoom, die primair behandeld zijn met radiotherapie en eventueel 
150 
Samenvatting en Conclusies 
chirurgische excisie, een .ILP met TNF en melphalan veilig en met bevredigend 
resultaat kan worden uitgevoerd. 
Het derde deel van dit proefschrift spitst zich toe op het laboratorium onderzoek 
dat wij hebben verricht om de moleculaire basis van het gebruik van TNF op te 
helderen. Vele studies hebben aangetoond dat TNF werkzaam is op het niveau 
van het endotheel in de tumor. In hoofdstuk 111.5 wordt een verklaring gegeven 
waarom niet aile tumoren in gelijke mate op TNF behandeling reageren, waarbij 
eens te meer gedemonstreerd wordt dat dit van tumor endotheel afhankelijk is. 
Het blijkt dat tumoren met een mindere mate van vascularisatie zeals 
bijvoorbeeld de colon carcinoom metastasen, minder gevoelig zijn voor 
behandeling met TNF. Door middel van dierexperimenten (ge"isoleerde lever 
perfusie in ratten met TNF en melphalan) wordt gedemonstreerd dat de 
concentratie van chemotherapeutica in de tumor afhankelijk is van de mate van 
vascularisatie van de tumor. In drie verschillende tumoren werden perfusies 
uitgevoerd, het CC531 coloncarcinoom, het ROS-1 osteosarcoom en het BN-175 
weke delen sarcoom. Hierbij werd de mate van vascularisatie bepaald met 
immunohistologie en het Hb-Assay. Hoge concentraties van melphalan werden 
gedetecteerd in de goed gevasculariseerde tumor, de BN-175, in vergelijking tot 
lage concentraties melphalan in de minder gevasculariseerde ROS-1 en CC531 
tumoren. De hoge melphalan concentratie in de BN-175 tumoren resulteerde in 
de meerderheid van de ratten met de BN-175 tumor tot een complete regressie 
van deze tumor na de perfusie. 
In eerdere hoofdstukken wordt reeds beschreven dat vascularisatie van een 
tumor een van de oorzaken is van de grate variatie tussen patienten die met een 
ge"isoleerde perfusie met TNF en melphalan behandeld zijn. Een andere oorzaak 
kan gevonden worden door te kijken naar de cytokine productie van de tumor 
zelf. EMAP II is een cytokine dat door tumoren geproduceerd wordt, en tenminste 
gedeeltelijk verantwoordelijk kan worden gehouden voor het verschil in respons 
op TNF. EMAP II is een relatief nieuw ontdekt cytokine, met vele interacties op 
het gebied van de angiogenese. Daarbij is aangetoond dat EMAP II secretie 
aanleiding geeft tot een opregulatie van de TNF receptoren op het tumor 
endotheel. In hoofdstuk 111.6 dient de vraag zich aan of in tumoren met weinig 
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EMAP II productie, deze door manipulatie van de tumor verhoogd kan worden. In 
het laboratorium hebben we experimenten verricht met een weke delen sarcoom 
in de rat dat relatief ongevoelig bleek te zijn voor de effecten van TNF. Nadat we 
van deze tumor retroviraal een kloon hadden geconstrueerd waarbij we in het 
genoom een EMAP II m-RNA konden incorporeren waarmee de expressie van 
EMAP II in deze tumor verhoogd werd, hebben we deze tumor gebruikt in de 
bestaande TNF perfusie modellen die we in de rat toepassen. De experimenten 
tonen een verbeterde tumor respons aan na een ILP met TNF als de expressie 
van EMAP II in de tumor hoger is. Het bleek dat de gevoeligheid van de tumor in 
vivo significant verhoogd was. 
In hoofdstuk 111.7 wordt beschreven dat het mogelijk is door middel van een 
retrovirale transfectie de prote"ine secretie in een tumor te verhogen. Het 
chemokine Interferon-inducible Protein-10 (IP-10) heeft anti-angiogene 
eigenschappen. Door retroviraal een humane melanomen cellijn te transfecteren 
met een IP-10 gen-construct werd de hypothese getest of door ophogen van een 
anti-angiogenetisch prote"ine in een tumor zijn groeisnelheid gereduceerd kon 
worden. Het bleek dat de vasculatuur in deze tumoren zodanig was afgenomen 
dat de groei van de tumor in een in vivo naakte muis model significant 
afgenomen was. Concluderend is het mogelijk gebleken in vitro een opregulatie 
te veroorzaken van een expressie van een gen, dat tot een verhoogde secretie 
van een functionerend cytokine in vivo leidt. Dit experiment Ievert tevens het 
bewijs voor de afhankelijkheid van de groeisnelheid van tumoren van cytokinen 
met angiogenetische werking. 
Hoofdstuk IV.8 behelst als laatste onderdeel van dit proefschrift de discussie. 
EMAP II, een nieuw cytokine met complexe interactie op het gebied van de 
angiogenese en tumorgroei wordt beschreven als een cytokine met een positief 
effect op tumornecrose, indien het in combinatie met TNF gebruikt wordt. 
lmplicaties en mogelijke klinische toepassingen worden uiteengezet. 
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CONCLUSIES 
• Het toevoegen van TNF aan de ge"isoleerde leverperfusie met melphalan 
resulteerde in een significant verschil in IL-6 en IL-8 productie in serum en 
perfusaat. 
• De toxiciteit die ten gevolge van het gebruik van TNF in de patient optreedt na 
een ge·isoleerde perfusie met TNF in de lever is mild en reversibel, waardoor 
TNF veilig kan worden toegediend mits deze dosis niet hager is dan 1 mg. 
Hierboven kunnen ernstige stollingsstoornissen optreden. 
'" ILP met TNF en melphalan kan leiden tot een goede klinische respons en 
behoud van de ledemaat in 80% van de patienten met irresectabele Stewart 
Treves angiosarcomen en moet als een behandelingsmodaliteit bij deze 
groep van patienten overwogen worden als alternatief voor amputatie. 
• Sarcoomrecidieven in bestraald gebied responderen nagenoeg even goed op 
extremiteitsperfusie met TNF en melphalan als niet eerder behandelde 
sarcomen. Deze behandeling leidt in 65% van de bestraalde patienten tot 
behoud van de ledemaat met goede functionele uitkomst en lage morbiditeit. 
• Retrovirale transfectie van humane melanomen met het anti-angiogenetisch 
chemokine I P-1 0 zorgt voor een functionele prote"ine secretie leidend tot 
remming van de groei van de tumor. 
• De mate waarin een tumor gevasculariseerd is, voorspelt mede de intra-
tumorale concentratie van een cytostaticum in de tumor na perfusie met TNF 
en melphalan. 
" Een hogere concentratie intra-tumorale melphalan verbetert in sterke mate de 
regressie van de tumor. 
" De sensitiviteit van een tumor voor TNF verbetert door de EMAP II productie 
van deze tumor te verhogen. 
" Onze resultaten rechtvaardigen verdieping van het onderzoek naar de 
klinische toepassing van EMAP II. 
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